Title:ChronicLowBackPainandMeditationNCT Record #:[STUDY_ID_REMOVED]Date: June 2, 2023PI:FadelZeidan
Biomedical IRBApplication InstructionsPage 2UCSDHumanResearchProtectionsProgramNewBiomedicalApplicationRESEARCHPLANInstructionsforcompletingtheResearchPlanareavailableontheHRPPwebsite.TheheadingsonthissetofinstructionscorrespondtotheheadingsoftheResearchPlan.GeneralInstructions:Enteraresponseforalltopicheadings.Enter“NotApplicable”ratherthanleavinganitemblankiftheitemdoesnotapplytothisproject.Versiondate:6/02/20231.PROJECTTITLETheroleofendogenousopioidsinmindfulness-basedchronicpainrelief.2.PRINCIPALINVESTIGATORFadelZeidan,AssistantProfessor,DepartmentofAnesthesiology3.FACILITIES*AltmanClinicalandTranslationalResearchInstitute(ACTRI).*UCSDCenterforMindfulness(CfM)4.ESTIMATEDDURATIONOFTHESTUDYWeestimatethattheproposedstudywilltake5yearstocomplete.Thisincludescompletingdatacollectionon60chroniclowbackpainpatients,dataanalyses,andtimeforpublication.Eachparticipantwillcomplete7studysessions,whichincludesreviewofmedicalrecordsforconfirmationofchroniclowbackpain,confirmationofstudyeligibility(i.e.,positiveresponsetothestraightlegraisetest,exclusion/inclusioncriteria),baselinepaintesting,fourdaysofmentaltraining(mindfulness/non-mindfulness)andtwoclinicalvisitswhereparticipantswillbeadministeredthestraightlegraisetestduringplacebo-salineornaloxoneinfusion.Afterallofthedatahasbeencollected,theinvestigatorsofthestudywillbeunblindedandstatisticalanalyseswillbeperformedtotestthestudyhypothesesatwhichpointwewillpreparethemanuscriptforpublication.Wedoexpectrecruitmenttogosmoothlyandanticipatethatdatacollectionwillbecompletedafter16monthswhichwouldprovideampletimefordataanalysesandmanuscriptpreparation.Withrespecttothesubjectfocusedstudyprocedures,a4-subjectcohortstrategywouldproduceastarttofinishaccrualprocessof1-2monthsorless.Anextra2-3weekswillbeaddedtothescheduleafteronecohortcompletestoallowfortherequiredaccrualofthenextgroupof8subjects.Thetotaloutsideaccrualboundaryofthisstudy,takingintoaccountincreasedstringencywithrecruitmenttowardstheendofthestudyandaccountingfora20%retentionloss,isatanestimateof12months.5.LAYLANGUAGESUMMARYORSYNOPSIS(nomorethanoneparagraph)Chronicpainaffectsover100millionAmericansandcoststheUnitedStatesanestimated$635billionperyearinmedicalexpensesandlostworkproductivity(InstituteofMedicine(US)CommitteeonAdvancingPainResearch2011,Steglitz2012).Lowbackpainisthemostcommonclinicalpaincondition(Hoy,Bainetal.2012)withanaverageprevalenceof30%;itistheleadingcausefordisability(Andersson1999).Inspiteoftreatmentadvances,thepervasivenessandburdenofchroniclowbackpain(cLBP)hasdramaticallyincreasedMedicareexpendituresforsteroidinjections(6 2 9 % )andopioidtreatments(4 2 3 % )(Deyo,Mirzaetal.2009).Thewidespreaduseofopioidstoalleviatechronicpainhasledtotheso-called“opioidepidemic”(Nelson,Juurlinketal.2015)withanexponentialriseinopioidmisuseandaddiction(Han,Comptonetal.2015,SalonerandKarthikeyan2015).Thesestaggeringstatisticssignifytheimportanceofdevelopingfast-actingnon-pharmacologicapproaches,suchasmindfulnessmeditation(Jacob2016),totreatacuteexacerbationsofcLBP.ThecentralaimoftheproposedNIHsponsoredstudyistodetermineifmindfulness-basedchronicpainrelief,ascomparedtonon-mindfulness,isassociatedwiththereleaseofendogenousopioids.ThisstudywillexamineifmindfulnessreducesacutelyevokedradicularpainincLBPthroughendogenous
Biomedical IRBApplication InstructionsPage 3opioids,ascomparedtoavalidated,non-mindfulnesstechniquethatwehavecharacterizedasnon-mindfulnessmeditation(Zeidan,Johnsonetal.2010,Zeidan,Emersonetal.2015).Theknowledgegainedfromthisstudywillprovidenovelmechanisticinsighttobetterdevelopandtailorcognitivetherapeuticinterventionstotargetmultiplechronicpainconditions.6.SPECIFICAIMSPrimaryObjectiveDetermineifmindfulness-basedchronicbackpainreliefismediatedbyendogenousopioids.7.BACKGROUNDANDSIGNIFICANCEPainisamultidimensionalexperiencethatinvolvessensory,cognitiveandaffectivefactors.Theconstellationofinteractionsbetweenthesefactorsrendersthetreatmentofchronicpainchallengingandoftenafinancialburden.Infact,chronicpainaffectsover100millionAmericansandcoststheUnitedStatesapproximately$635billiondollarsayear.Thewidespreaduseofopioidstotreatchronicpainhasledtotheso-called“opioidepidemic”duetotheexponentialgrowthinopioidmisuseandaddiction.Thesestaggeringstatisticshighlighttheimportanceofdeveloping,testingandvalidatingfast-acting,non-pharmacologicalapproachestotreatpain.Mindfulnessmeditationisatechniquethathasbeenfoundtosignificantlyreducepaininexperimentalandclinicalsettings.However,lackofmechanisticdataandtheassumptionthatextensivemeditationtrainingisrequiredtoexperienceanalgesiahaslimitedtheclinicaldeploymentofthiscost-effectiveandnarcotic-freetreatment.Recentfindingsfromourlaboratorydeterminedthatmindfulnessmeditationreducespain(meanpainintensity=34%;meanpainunpleasantness =51%),afteronly4trainingsessions,throughmultiplebrainmechanisms(Zeidan,Martuccietal.2011,Zeidan,Emersonetal.2015).Wehavealsofoundthata)mindfulness-basedpainreliefismoreeffectiveandmechanisticallydistinctfromplacebo-analgesiaandb)surprisingly,mindfulnessmeditationdoesnotengageendogenousopioidergicsystemstoreducepain(Zeidan,Adler-Nealetal.2016,May,Koseketal.2018).Yet,thesefindingsaredifficulttoexplicitlygeneralizetochronicpainpatientsbecausetheywereconductedinpain-freeindividualsusingthermallyinducedpain.Theexperienceofpainpromotesendogenousopioidreleaseinhealthyindividuals(Zubieta,Smithetal.2001,Anderson,Shethetal.2002,Bencherif,Fuchsetal.2002,Zubieta,Smithetal.2002).Incontrast,thereisrobustevidencethatopioidreceptoravailabilityissignificantlyreducedinthebrainacrossawidespectrumofchronicpainconditions(Jones,Cunninghametal.1994,Jones,Kitchenetal.1999,Jones,Watabeetal.2004,Harris,Clauwetal.2007,Maarrawi,Peyronetal.2007,Klega,Eberleetal.2010,DosSantos,Martikainenetal.2012,Brown,Matthewsetal.2015),includingchroniclowbackpain(Bruehl,Chungetal.2003,BruehlandChung2006,Bruehl,Chungetal.2007,Martikainen,Pecinaetal.2013,Bruehl,Burnsetal.2015,Burns,Bruehletal.2017),thecausepostulatedtobethedevelopmentofchronicpain(Thompson,Pitcheretal.2018).However,whilewehaverepeatedlyshownthatmindfulnessdoesnotemployendogenousopioidstoreducepaininhealthysubjects,itisalsopossiblethattheroleofendogenousopioidsinmindfulness-basedanalgesiaismorepronouncedinclinicalpainpopulations.Thus,thecentralaimoftheproposedstudytodetermineifmindfulness-basedcLBPrelief,themostprevalentandfinanciallyburdensomechronicpaincondition,ismediatedbyendogenousopioids.Theuseofhighdosenaloxoneiscommonplaceandroutinelyemployedinmechanisticallyfocusedpainresearchforover40yearsnow(citationsselectedoutof>1000studies)(GoldsteinandGrevert1978,Skrabanek1978,Gracely,Dubneretal.1983,PosnerandBurke1985,LevineandGordon1986,Benedetti1996,AmanzioandBenedetti1999,Amanzio,Polloetal.2001,Bruehl,Chungetal.2004,Bruehl,Burnsetal.2008,Burns,Bruehletal.2009,Bruehl,Burnsetal.2011,Taylor,Borckardtetal.2012,Pereira,Werneretal.2013,Schoell,Bingeletal.2013,Dowell,Haegerichetal.2016,Springborg,Jensenetal.2016,Zeidan,Adler-Nealetal.2016,Berna,Leknesetal.2018,May,Koseketal.2018)(Grevert,Albertetal.1983,AmanzioandBenedetti1999,Benedetti,Arduinoetal.1999)(Adams1976,Hosobuchi,Adamsetal.1977)(deAndrade,Mhallaetal.2011,Taylor,Borckardtetal.2013)(Mayer,Priceetal.1977)(Stephenson1978).Naloxoneatahighdoesprovidescompleteblockadeofopioidreceptorswhichallowsustoidentifytheroleofendogenous
Biomedical IRBApplication InstructionsPage 4systemsintheconstructionandmodulationofpain.Ifwedonotcomprehensivelyblockendogenousopioids,thenwewillnotbeablereliablyinferenceourresultstotherecruitment(orlackthereof)ofendogenousopioidsinmindfulness-basedpainrelief(Grevert,Albertetal.1983,SpiegelandAlbert1983).Fortunately,naloxonedoesnotproducesignificantsideeffectsinopioidindependentparticipants(Mangold,McCauletal.2000)andthusweprobetheroleofendogenousopioidsquitereliably.Thisworkcouldguidefutureclinicaltrial(s)developmenttobettertargetoutcomesandcorrespondingmechanisms supporting meditation-related cLBP relief. If meditation induced chronic pain relief wereassociatedwithnon-opioidergicmechanisms,itwouldprovidesignificantevidencethatmindfulnessrelievespainbyalteringthecontextualevaluationofnociceptiveinformationviauniquetop-downcontrolprocesses(Zeidan,Grantetal.2012).Sinceopioidandnon-opioidmechanismsofanalgesiainteractinasynergisticmanner,thepresentworkcouldshowthatthecombinationofmindfulnessandpharmacologic/non-pharmacologicanalgesicstrategies,thatrelyonopioidsignaling,maybeacutelyeffectiveinthetreatmentofclinicalpain,apotentiallycriticalfindingforthemillionsofpainpatientsseekinganon-opioidtherapy.8.PROGRESSREPORTNotapplicable.Thisisanewstudy.9.RESEARCHDESIGNANDMETHODSThisproposedNIH-sponsored,randomized,anddouble-blindedpsychophysicalandpharmacologicstudyincludes7separatestudysessions.Inthisexperiment,weareassessingifmindfulnessreducesacutelyevokedradicularpainincLBPthroughendogenousopioidsascomparedtoavalidated(Zeidan,Johnsonetal.2010,Zeidan,Emersonetal.2015),non-mindfulnessmeditationtechnique(non-mindfulness)byadministeringanopioidantagonist,naloxone,todetermineifmindfulnessbasedcLBPreliefismediatedbyendogenousopioidergicsystems.Importantly,weareemployingawell-validated,non-mindfulnessmeditationinterventionasaplacebocontrol.Aspreviously(Zeidan,Johnsonetal.2010,Zeidan,Emersonetal.2015),thenon-mindfulnessgroupwillbeinstructedthattheyareinthe“mindfulnessmeditation”intervention.Thus,wemustblindnon-mindfulnesssubjectstothenatureoftheirrespectiveintervention.Eachstudysessionwillbeconductedonaseparateday.Allpotentialparticipantswillbeassessedforstudyeligibilityatthepre-studyscreeningandfirststudysession.Participantswillhave40daystocompletethestudy.Exemptionfrom21CFR312.2(b)(iii):Weandmanyothergroupsareexemptfromkeycriterionoutlinedin21CFR312.2(b)(iii)(Theinvestigationdoesnotinvolvearouteofadministrationordosageleveloruseinapatientpopulationorotherfactorthatsignificantlyincreasestherisks(ordecreasestheacceptabilityoftherisks)associatedwiththeuseofthedrugproduct)becausethedosageemployedhasbeenrepeatedlydemonstratedtobehighlysafeandeffectiveatexaminingthestudyaims.ThisisdemonstratedbelowanddescribedintheattachedINDExemptsupplementdocument(item25).Critically,theuseofhighdosenaloxoneiscommonplaceandroutinelyemployedinmechanisticallyfocusedpainresearchforover40yearsnow(citationsselectedoutof>1000studies)(GoldsteinandGrevert1978,Skrabanek1978,Gracely,Dubneretal.1983,PosnerandBurke1985,LevineandGordon1986,Benedetti1996,AmanzioandBenedetti1999,Amanzio,Polloetal.2001,Bruehl,Chungetal.2004,Bruehl,Burnsetal.2008,Burns,Bruehletal.2009,Bruehl,Burnsetal.2011,Taylor,Borckardtetal.2012,Pereira,Werneretal.2013,Schoell,Bingeletal.2013,Dowell,Haegerichetal.2016,Springborg,Jensenetal.2016,Zeidan,Adler-Nealetal.2016,Berna,Leknesetal.2018,May,Koseketal.2018)(Grevert,Albertetal.1983,AmanzioandBenedetti1999,Benedetti,Arduinoetal.1999)(Adams1976,Hosobuchi,Adamsetal.1977)(deAndrade,Mhallaetal.2011,Taylor,Borckardtetal.2013)(Mayer,Priceetal.1977)(Stephenson1978).
Biomedical IRBApplication InstructionsPage 5Inaddition,ourlaboratoryhasnowsuccessfullycompletedthreeseparateexperimentscombiningnoxiousstimulation,mindfulness-basedmeditation(andsham-mindfulness),andIVnaloxone/salineinfusionemployingtheexactproceduresthatmatchthisNIHsponsoredproject.Inourfirsttwopublishedstudies(Zeidan,Adler-Nealetal.2016,May,Koseketal.2018),weemployedtheexactnaloxonedosagesandprocedures(verysafely)astheonesforthisstudy.Wehaverecentlycompleted(datacollectioncompleted;writingmanuscriptnow)athirdstudy,whereweemployedwhatwe(andtheNIH)characterizedasacross-overdesign,naloxoneinfusionprocedurein60individualswithoutanysafetyevents.ThefourparticipantsthatexhibitedsideeffectsinourJournalofNeuroscience,2016studywasrelatedtothesesubjects’previoushistoryofsyncope,fearofneedles,andbloodandnotdirectlyrelatedtonaloxone.Thus,inourlateststudy(inpreparation),weexcludedindividualsthathavenopriorhistoryofsyncope,fearofblood/needles,andreportnosideeffects,safetyand/oradverseevents.Further,thenaloxonedosagesemployedinourlaboratorystudiescorrespondedtoa0.15mg/kgbolusdoseofnaloxone(NaloxoneHCI,AmphastarPharmaceuticals,Inc.,RanchoCucamonga,California)orsalinein25mlnormalsalinewasadministeredover10minutesviatheintravenous(IV)lineinsertedintotheantecubitalveinofthenon-dominantarm.Toensurethatnaloxoneantagonizesopioidreceptorsforentiretyoftheexperiment,weadministeredasupplementaryIVinfusiondoseof0.1mg/kg/hournaloxoneorsalineimmediatelyafterbolusinfusionceasedtilltheendoftheexperiment.Thislargedosecomprehensivelyantagonizesendogenousopioids(LevineandGordon1986)andreversespainreliefproducedbyplacebo(Levine,Gordonetal.1978,Grevert,Albertetal.1983,AmanzioandBenedetti1999,Benedetti,Arduinoetal.1999),electricalstimulationofperiventriculargraymatter(Adams1976,Hosobuchi,Adamsetal.1977),transcranialmagneticstimulation(deAndrade,Mhallaetal.2011,Taylor,Borckardtetal.2013),acupuncture(Mayer,Priceetal.1977),andhypnosis(Stephenson1978).InourthirdstudyconductedattheUniversityofOregon,weusedanevenlargerdosageof0.15mg/kgbolusdoseofnaloxone(NaloxoneHCI,AmphastarPharmaceuticals,Inc.,RanchoCucamonga,California)witha.20mg/kg/hourinfusion.Therewerenosideeffectsexhibitedinthisstudy.Further,othergroups(Mangold,McCauletal.2000,Eippert,Bingeletal.2009,Schoell,Bingeletal.2013,Berna,Leknesetal.2018)haveemployedlargerIVdosagesofnaloxonethanourprotocolwithoutanysideeffectsoradverseevents.Wehaveextensivelypilotedourprocedurestoensurethatnosideeffectsarise,wedonotunblindsubjectsandcancomprehensivelyblockendogenousopioids.Wehaverunover180participantswithonlyfourminorsideeffectsinastudywherewedidnotexcludesubjectswithpriorhistoryofsyncope,fearofbloodand/orneedles.Wewillemploythisnewexclusioncriteriainthepresentstudy.DurationofHumanInvolvementSuccessfulcompletionoftheproposedstudywillincludeatotalof7sessions.Priortotheirenrollmentpotentialsubjectswillfirstbescreenedoverthephonetodetermineiftheyqualifyfortheproposedproject.Theremaybeupto2weeksbetweenapatient’sinitialscreeningandtheirofficialenrollmentofthestudy.Wewillprovideuptoa14-daygapbetweenenrollmentandthefirstexperimentalsessiontoprovidetimetoenrollcohorts,grouprandomization,andindividualizedscheduling.Oncethescheduleshavebeendetermined,theparticipants’baselineassessmentandbaselinetestingsessionwillbescheduled,andcoordinatorstudyteammemberwillscheduleinterventionregimens.Studyparticipantswillberequiredtocomplete4respectivetrainingsessionsovera14-dayperiod(includingweekends;interventionswillbeofferedovertheweekend).Thisapproachwillincreasestudyfeasibility,complianceandadherence.Theclinicalpharmacologictestingsessionswillbescheduled
Biomedical IRBApplication InstructionsPage 6individuallyduringtherespectiveinterventions.Afterthefirstpharmacologictestingsession,participantsmustwaitnolessthan2daysandnomorethan6daystocompletethesecondclinicalpharmacologictestingsession.PlannedDataCollectionDataCollection:Thefollowinginformationwillbecollectedfromallpatients:name,dateofbirth,age,gender,ethnicity,telephonenumberemailaddress,medicalrecordnumber(willbedeletedfromstudyfileoncereviewofmedicalrecordsiscomplete),diagnosis,condition,current/previousdrugregimen,handednessandmeditationexperience.Also,inordertoprocesssubjectcompensation,addressandsocialsecuritynumberwillbecollected.ExperimentalSessions:Alloftheproposedproceduresarecharacterizedas“experimental”.Session1Pre-RegimenSession:SubjectswillfirstreporttotheAltmanClinicalandTranslationalResearchInstitute(ACTRI).Thissessionwillalsobeemployedtodetermineparticipanteligibilitybasedonourinclusionandexclusioncriteriaandwillserveasthebaselinebehavioralcontrol.Afterobtaininginformedconsent,subjectswillcompletestudyquestionnaires(seeQuestionnaires)andwillbetrainedtoreliablyusethevisualanalogscale(VAS)toratetheirpain(Zeidan,Martuccietal.2011,Zeidan,Emersonetal.2015,Zeidan,Lobanovetal.2015),inresponsetoheatstimuli(32stimuliof5secondduration)rangingfrom35-49°Cinafixedorder,andthechroniclowbackpainexacerbationprocedure.Thispsychophysicaltrainingwillalsomaximizereproducibilityofpainratings(Rosier,Iadarolaetal.2002).Theseassessmentswillbebasedonself-report,reviewofmedicalhistoryfromthesubject’scurrent/previousphysician(s),and/orconfirmationofchroniclowbackpaindiagnosisbyastudyphysicianduringSession1attheACTRI.Inthereviewofasubject’smedicalhistory,atrainedstudystaffmemberwillreviewandrecordnecessarydata,inordertoconfirmeligibilitycriteriaaremet.InformationwillbereviewedfromtheEPICmedicalrecordsofsubjectswhoareUCSDpatientsorfromcopiesofthemedicalrecordsprovidedbynon-UCSDpatientsubjects.Theseoutcomesinclude:thesubject’sdiagnosis(spinalpathologyanddate),condition,andcurrent/previousdrugregimen.Confirmationofchroniclowbackpainmustalsobedeterminedthroughperformanceofthestraightlegraisetest.Thatis,astudyphysician(KrishnanChakravarthy)ortrainedresearchtechnicianswillconfirmdiagnosisbyexaminingthemedicalhistoryrecord.Ifamedicalrecordisnotavailable,thenwewillconfirmlowbackpainbydeterminingifthepatientis“positive”onthestraightlegraisetest,whichwillserveastheprimarymethodoflowbackpainconfirmation.AsdescribedinSession1,wewilltesttoseeifthestraightlegraisetest(SLR)producesanincreaseinsubjectivepaincorrespondingtothelowback.Subjectsthatreportanincreaseofpainwhenliftingtheirlegsupfrom15-60degrees,ortoaheightinthatrange,willbecharacterizedas“straightlegraisetestpositive.”Thisisanindicatorofradicularpainstemmingfromthelowback.PsychophysicalTestingThermalstimulation:AsinallofourpriorIRBapprovedexperiments(Zeidan,Martuccietal.2011,Lobanov,Zeidanetal.2014,Zeidan,Emersonetal.2015,Zeidan,Lobanovetal.2015,Zeidan,Adler-Nealetal.2016,Zeidan,Salomonsetal.2018,Adler-Neal,Emersonetal.2019,Adler-Neal,Waughetal.2019),theMEDOCTSA-IIwillbeusedtodeliverallthermalstimuli.Allstimulustemperatureswillbelessthanorequalto50°C,andvolunteerswillbefreetoescapethestimulatoratanytime.Nostimuluswillproducetissuedamage.Thisstudywillusea16x16mmsurfaceareaforthedeliveryofneutralandnoxiousstimuli.Thismodeststimulusareaallowsarelativelywiderangeofnoxiousstimulitobedelivered(upto50°Cfor30seconds)withouteithertissuedamageorsignificantsubjectwithdrawals/drop-outs.StimuliinthistemperaturerangehavebeenusedextensivelybythePI
Biomedical IRBApplication InstructionsPage 7andnumerouslaboratoriesaroundtheworldanddonotproducetissuedamageorburns.Inordertofacilitateescapefromthestimulator,thestimulatorwillbeattachedtoacustom-designedthermalstimulationprobeholder.Participantswillplacetheircalfontopoftheprobeholderandwillnotbestrappedinorotherwiserestrained.Therefore,participantswillbeabletosimplylifttheirlegsatanytime.Chroniclow-backpainexacerbationprocedure:Co-investigatorsand/ortrainedstudystaffwillconductthecLBPexacerbatingstraightleg-raisetest,whichiscommonlyusedtoassessmobilityandpainseverityinthosewithlow-backpain(Mens,Vleemingetal.1999,Roussel,Nĳsetal.2007,Kwong,Viranietal.2013,Bruno,Millaretal.2014).Thisproceduresignificantlyincreasesbehavioralandneuralpainresponsesfor10-15minutes(Apkarian,Kraussetal.2001,Sharma,Guptaetal.2011,Wasan,Loggiaetal.2011,Loggia,Kimetal.2013).Session1willdetermineifthestraightlegraisetestwillreliablyexacerbatecLBPandallowpatientstodecideiftheyarewillingtoperformsubsequentstraightlegraises.Co-investigatorsand/ortrainedstaffwillfirstinstructpatientstolieinsupinepositionfor15secondsbeforecollectingbaselinepainratings.Foreachpatient,wewillfirstmeasurethestraightlegangle/heightrequiredtoproducea2-pointVASpainintensityincreaseusingagoniometer[70].Withtheaidofstudystaff,participantswillagainperformastraightleg-raiserangingfrom15-60°(Rebain,Baxteretal.2002,Summers,Malhanetal.2005),dependingontheangle/heightrequiredtoproducethetargetedpainincreaseandholdthepositionfor10seconds.Afterloweringtheirlegs,wewillassessifthepatient’spainratingsincreasedtothetargetedpainincreasecomparedtobaselinepainratings(Wasan,Loggiaetal.2011).Thisprocedurewillberepeateduptothreetimestoensureinter-maneuverreliability(Wasan,Loggiaetal.2011).Sincethisprocedurecanexacerbatepainforupto15minutes,wewillwaitatleast20minutesbetweenteststoconfirmthatpainreturnedtobaseline.Theleg-raiseangle/heightcorrespondingtoa2-pointVASpainincreasewillbetargetedineachsubsequenttestingsession.Thissessionshouldtakeapproximately2.0hoursorlesstocomplete.ProceduresPreRest+Heat:Athermalprobewillbeplacedonthebackofthe“unaffected”calf(i.e.,non-responsivetoSLR)whilepatientslieinthesupineposition.Theywillbeinstructedto“restwithyoureyesclosed”for5minutes.Wewilladministertheso-called“Heat”seriesthatincludes10alternating,12-secondplateausofnoxious(49°C)and35°Cstimulation.VASpainintensity,VASunpleasantness,andnumericalpainratingswillbecollectedaftertheserieshascompleted.Wewillthenremovethecalffromtheprobeholder.PreRest+SLR:Afteridentifyingtheappropriateangle/heighttoinducea2-pointpainincrease,patientswilllieinthesupinepositionandwillbeinstructedto“restwithyoureyesclosed”for5minutes.VASpainratingswillthenbecollected.Withtheaidofatechnician,patientswillthenlifttheirlegstotheangle/heightcalibratedtoproducea2-pointVASpainincrease.After5minutes,wewillcollectpainratings.PostRest+SLR:Wewillwait10minutesbeforecontinuingthestudytocontrolforthetimespentadministratingthedrug/salinebolustakeeffect.VASpainratingswillbecollectedafter10minutes.WewillthenmatchtheproceduresemployedinPre-Rest+SLR.PostRest+Heat:Athermalprobewillbeplacedonthebackofthe“unaffected”calfwhilepatientslieinthesupineposition.Theywillbeinstructedto“restwithyoureyesclosed”for8minutes.WewillthenmatchtheproceduresemployedinPreRest+Heat.PatientRandomization:Aftersuccessfulcompletionofsession1,participantswillberandomizedtotheirrespectivegroup.RandomizationwillbetrackedintheScreening/EnrollmentLogthatismaintainedbytheclinical
Biomedical IRBApplication InstructionsPage 8coordinator.Randomizationwillbestratifiedsothateachsexwillhavetheirrespectivelistofrandomizationcodes.Malesandfemaleswillberandomizedwithoutreplacementacrossablockof60codesusinganExcel-basedrandomnumbergenerator.Maleandfemaleparticipantswillberandomizedwithinthreedaysoftheirrespectivescheduledpsychophysicaltrainingsession.Thetwotreatmentarms(mindfulnessmeditation=A;non-mindfulnessmeditation=B)willbepermutedwithrespecttotreatmentassignment,inadouble-blindfashion,respectively.Wewillemployasimilarrandomization procedure within each groupto determine when (i.e., Session6o r7 )e a c hp a r t i c i p a n twillreceivenaloxoneandsalineinacrossovermanner.Sessions2-5:Regimen:Procedurescorrespondingtotheregimensessionswillparallelthemindfulnessmeditationandnon-mindfulnessmeditationtrainingregimensemployedpreviously(Zeidan,Emersonetal.2015).Interventionswillbeconductedingroupsofone(1=makeupsessions)tosix(Zeidan,Gordonetal.2010,Zeidan,Johnsonetal.2010,Zeidan,Johnsonetal.2010,Zeidan,Martuccietal.2011,Zeidan,Martuccietal.2014,Zeidan,Emersonetal.2015)andtaughtbycertifiedfacilitatorsattheUCSDCenterforMindfulness(CfM).AresearchtechnicianwillgreetpatientsastheyarrivetotheCfMandguidethemtotheirrespectiveclassrooms.Bothpriortoandaftercompletionofeachinterventionregimen,theresearchtechnicianwillissueandcollectstudyassessmentdata(SAIbothpreandpost-interventionsession;PerceivedInterventionEffectivenesspost-interventionsession)toeachparticipant.Eachofthesesessionswilltakenolongerthan45minutestocomplete.MindfulnessMeditationTraining:Wewilluseourwell-validatedmindfulness-basedmentaltrainingregimentoteachparticipantstoindependentlypracticemindfulnessmeditation(Zeidan,Johnsonetal.2010,Zeidan,Johnsonetal.2010,Zeidan,Martuccietal.2011,Zeidan,Emersonetal.2015,Zeidan,Adler-Nealetal.2016).Ineachofthefour20-minutesessions,participantswillbeaskedtoclosetheireyes,focusonthebreathsensations,recognizedistractingthoughtsandfeelings,andto“simplyletgo”ofsensoryeventswithoutjudgment.Theywillbetaughtthatperceivedsensoryandaffectiveeventsare“momentary”and“fleeting”anddonotrequireevaluation.Non-mindfulnessMeditationTraining:Themainpurposeofthenon-mindfulnessmeditationregimenistoserveasanactivecontrolforacrucial,essentialelementofmindfulnessmeditation(i.e.,mindfulattentiontobreathandnon-reactivitytosensoryevents)(Zeidan,Johnsonetal.2010,Zeidan,Emersonetal.2015).Thisregimenisdesignedsothattheprimarydifferencebetweenthemindfulnessandnon-mindfulnessmeditationtrainingisthemindfulnessmeditationgroup’sexplicitmindfulness-basedinstructions(e.g.,mindfulattentiontothebreath).Thenon-mindfulnessmeditationgroupwillbetoldthattheyarerandomlyassignedtothemeditationgroup(Zeidan,Johnsonetal.2010,Zeidan,Emersonetal.2015).Ineachofthefour20-minutetrainingsessions,participantswillbeinstructedtoclosetheireyes,andtotakeadeepbreath“aswesithereinmeditation”every2-3minutes(Zeidan,Johnsonetal.2010,Zeidan,Emersonetal.2015).Allotheraspects(trainingroom,posture,facilitator,timeprovidinginstruction)ofthenon-mindfulnessmeditationinterventionwillbematched.Sessions6&7:Post-RegimenSession:Wewillemployadouble-blindedcrossoverdesigntocorrespondtotheadministrationoftheopioidantagonist,naloxoneandplacebo-salineacrosstwoseparatesessionsatUCSD’sAltmanClinicalandTranslationalResearchInstitute(ACTRI).Atotalof30subjectsineachgroupwillreceivenaloxoneinSession6andsalineinSession7.Conversely,theother30subjectsineachgroupwillreceivesalineinSession6andnaloxoneinSession7.Aftersuccessfulcompletionoftheirrespectiveregimen,participantswillreporttotheACTRI.AresearchtechnicianwillgreetpatientsastheyarrivetotheACTRIandguidethemtotheclinicroom.Next,theresearch technician will issue study assessments to the participant.ACTRI nurses will then administeranopiate-focusedurinedrugscreeningtoconfirmthatnoparticipantsareusingopioidstoremovetheriskofopioidwithdrawalsymptomsduringnaloxoneadministration,andapregnancytest(ifapplicable).Weightwillbesubsequentlymeasuredtoconfirmtheprescribeddrugdosage.Next,the
Biomedical IRBApplication InstructionsPage 9researchtechnicianwillissuestudyassessmentstothesubject.Wewillrecalibrateeachparticipant’slegraiseheight/anglerequiredtoelicita2-pointpainincreaseemployingthemethodsdescribedinSession1.AnACTRInursewilltheninserttheIVcatheterintothenon-dominantarmofeachparticipant.Aspreviouslyemployed(Zeidan,Adler-Nealetal.2016)forsafetypurposes,bloodpressure,respiration,oxygensaturation,andheartratewillbesystematicallymonitored/recorded.Thesesessionsshouldtakeapproximately1.0hourtocomplete.PreRest+Heat:Athermalprobewillbeplacedonthebackofthe“unaffected”calfwhilepatientslieinthesupineposition.Theywillbeinstructedto“restwithyoureyesclosed”(~5minutes).Wewilladministera“Heat”seriesthatincludes10alternating,12-secondplateausofnoxious(49°C)and35°Cstimulation.Aftercompletion,wewillcollectpainratings.PreRest+SLR:TheproceduresemployedinPreRest+SLRwillbematchedtothoseemployedinSession1.Briefly,patientswilllieinthesupinepositionandbeinstructedto“restwithyoureyesclosed”.VASpainratingswillthenbecollected.Withtheaidofatechnician,participantswillthenlifttheirlegstotheangle/heightcalibratedtoproducea2-pointVASpainincrease.Aftercompletion,wewillcollectpainratings.Bolus:AnACTRInursewilltheninitiatethenaloxone/salinebolus(basedonweight)forapproximately8minutes.PreMeditation+SLR: Aftercompletionofthebolus(~8minutes),astudytechnicianwillaidparticipantstolifttheirlegstotheheight/anglecalibratedtoproducea2-pointVASpainincrease.Participantsinthemindfulnessandnon-mindfulnessmeditationgroupswillthenbeinstructedto“beginmeditatinguntiltheendofthesession”(Zeidan,Martuccietal.2011,Zeidan,Emersonetal.2015).AnACTRInursewilltheninitiatethenaloxoneorplacebo-salineinfusion.Aftercompletion,wewillcollectpainratings.PostMeditation+Heat:Athermalprobewillbeplacedonthebackofthe“unaffected”calfwhilepatientslieinthesupinepositionandduringmeditation.Wewilladministera“Heat”seriesthatincludes10alternating,12-secondplateausofnoxious(49°C)and35°Cstimulation.Aftercompletion,wewillcollectpainratings.PatientswillreturntotheACTRItocompletesession7andwillfollowthesameprocedures(exceptfordrugadministration)asSession6.Participantsmustwait2daystoparticipatebutnolongerthan7daystocompleteSession7.Drugsymptomologywillbeassessedaftereachsession.PrimaryOutcomeMeasure(s):1.VisualAnalogScale(VAS)andnumericalratingscales(NRS):Painratings(VASpainintensity,VASunpleasantness,andnumericalpainratings)willbeassessedinresponsetothestraightlegraisetest.2.exploratoryoutcomesincludethosecorrespondingto“heatinducedpainratings”(i.e.thermalstimulation),andlyingsupine.Theminimumrating("0")isdesignatedas"nopain"whereasthemaximum("10")islabeledas"mostintenseimaginable"or"mostunpleasantimaginable.”Highernumberscorrespondtohigherpain.a.WewillcollectnaloxoneandsalineinducedchangesinpainintensityandpainunpleasantnessratingsSample Size Determination:Ourtargetedsamplesizeis60cLBPpatients(30/group).Toconductgroupcomparisonsamongthetwoprimaryoutcomes(naloxone+salineinducedchangesinpainintensity+unpleasantness)andtoensureanoveralltypeIerrorrate<0.05,weusedconservativeBonferronicorrections(p=.025)inallpowercalculations.Employingthepilotdatacorrespondingtoourpreviouswork(Wellsetal.,2020),wefitrepeatedmeasuresANOVAmodelsthatincludeindicator
Biomedical IRBApplication InstructionsPage 10variablesforgroup(mindfulnessvs.sham)anddrug(naloxonevs.saline).Theestimatedsquarerootofmeansquareerrorsis0.23(23%)and0.30(30%)forpainintensityandpainunpleasantness,respectively.Thirtysubjectswillprovide80%powertodetectapainratingdifferenceof22%betweenthenaloxoneandsalineconditionsinthenon-mindfulnessgroupwithanestimatedSDof0.3(30%).Weexpectnomeaningfuldifferencesinpainreductionsbetweennaloxoneandsalineinfusionduringmindfulnessmeditation.Thus,wewillhave80%powertodetectasignificantgroupXdrugtypeinteraction.Finally,30subjects/groupwillprovide80%powertodetectasignificantgroupdifferenceof19%forpainintensityand24%forpainunpleasantness.Sucheffectsizesparallelthoseobservedinourpilotdata(Wellsetal.,2020).Statisticalpowerwillbealsogreaterwhenpre-regimenpainratingsareenteredascovariatestoreduceresidualvariance.QuestionnairesforStudyAssessments:AllquestionnaireswillbedeliveredusingResearchElectronicDataCapture(REDCap)oniPadtabletsadministeredandsupervisedbystudypersonnel.Afteranumberofpilottrialsinourlaboratory,thetotalamountoftimetocompleteallassessmentsaveraged30minuteswitharangeof25-45minutes.ThequestionnairestobepresentedontheREDCapplatformincludethefollowing:2.FiveFacetMindfulnessQuestionnaire(FFMQ):Thisisa39-itemmultidimensionalmeasureoftraitmindfulnessandincludesfivesubscales:non-reactivity,nonjudgement,describing,observing,andactingwithawareness.3.ProfileofMoodStatesQuestionnaire(POMS-shortform):Thisisa40-itemmeasureof6moodstates:tension-anxiety,depression-dejection,anger-hostility,vigor-activity,fatigue-inertia,andconfusion-bewilderment.ThisassessmentisrecommendedbytheIMMPACTgroupasacoremeasureofemotionalfunctioning.4.Subjects’GlobalImpressionofChange(PGIC):Thisisaself-reportassessmentrecommendedtoevaluateself-reportedperceptionofimprovementovertrial/efficacyoftreatment.5.PainSelfEfficacyQuestionnaire(PSEQ):Thisisa10-itemquestionnairethat’sdesignedtoassessconfidenceinperformingactivitieswhileinpain,forthosewithongoingpain.6.PROMIS29-ItemProfile:Thisisa29-itemgenerichealth-relatedsurveythatassessesthefollowing7domains:depression,anxiety,physicalfunction,paininterference,fatigue,sleepdisturbance,andabilitytoparticipantinsocialroles/activities.7.PROMISPainBehaviorMeasure:Thisisa5-itemquestionnairethatmeasurescomplaintsofsuffering,verbalornonverbal(i.e.suchaswhenIaminpainIsquirm),fromthepast7days.8.PROMISPhysicalFunctionMeasure:Thisisa13-itemself-reportassessmentthatmeasurescapabilityratherthanactualperformanceofphysicalactivities.9.PROMISPainQualityMeasure:Thisisa5-itemquestionnairethatmeasuressensoryqualityofpainexperience(throbbing,aching,etc).10.ChronicPainAcceptanceQuestionnaire(CPAQ-R):Thisisa20-itemassessmentdesignedtomeasureacceptanceofpain.Theacceptanceofchronicpainisthoughttoreduceattemptstoavoidorcontrolpainandthusfocusonengaginginvaluedactivities.11.StateAnxietyInventory(SAI):TheSAIisaprominent20-itemmeasureforanxiety,andwillbeutilizedasamanipulationcheckforourbehavioralinterventions.12.BriefPainInventory(BPI):Thisisan8-itemassessmentwidelyusedtomeasureclinicalpain.13.SF-12HealthSurvey(SF-12):Thisisa12-itemversionoftheSF-36itemHealthSurveydesignedtoassessgeneralmentalandphysicalfunctioning,andoverallhealth-relatedqualityoflife.14.PainCatastrophizingScale(PCS):Thisisa13-itemassessmentderivedfromdefinitionsofcatastrophizing.ThePCSyieldsatotalscoreandthreesubscalescoresassessingrumination,magnification,andhelplessnessinsubjects.15.BeckDepressionInventory(BDI):Thisisa21-itemstandardassessmentwidelyusedtomeasureclinicaldepression.16.TheFreiburgMindfulnessInventory(FMI):Thisisa14-itemstandardmindfulnessscaletomeasurepotentialchangesinmindfulnessbeforeandafterintervention.
Biomedical IRBApplication InstructionsPage1117.Roland-MorrisDisabilityQuestionnaire(RMDQ):ThisisacriticalassessmentforthechroniclowbackpainphenotypeandwasrecommendedforusebytheNIH.18.PittsburghSleepQualityIndex(PSQI):Thisisa10-itemassessmentdesignedtomeasurequalityofsleep.19.CohenPerceivedStressScale(PSS):Thisassessmentiscriticalforcontrollingstressinouranalysesaswellasapotentialpredictorinclinicalpainimprovements20.MultidimensionalAssessmentofInteroceptiveAwareness(MAIA):Thisisa32-itemmultidimensionalinstrumentthatincludes8scalesrangingfrom3to7itemseach.Thescalesarenoticing,not-distracting,not-worrying,attentionregulation,emotionalawareness,self-regulation,bodylistening,andtrusting.21.NondualAwarenessDimensionalAssessment(NADA):Thisisa13-itemstandardizedinstrumentcapableoffacilitatingquantitativeinvestigationofnondualawarenessusingtwodimensions:blissandself-transcendence.22.SocialConnectednessScale(SCS):Thisisa20-itemassessmentdesignedtomeasuresocialconnectedness,anattributeoftheselfthatreflectscognitionsofenduringinterpersonalclosenesswiththesocialworld.DrugAdministration:AllstudieswillbeconductedwiththesupervisionofACTRInursesintheACTRI.Aspreviouslyconducted(Zeidan,Adler-Nealetal.2016),a0.15mg/kgbolusdoseofnaloxone(NaloxoneHCI,AmphastarPharmaceuticals)or25mlofnormalsalinewillbeadministeredover10minutesviatheIVlineoftheantecubitalveinofthenon-dominantarm.Onsetofnaloxone-inducedopioidergicantagonismoccurswithin2minofinfusionandexhibitsanaveragehalf-lifeof64min(Ngai,Berkowitzetal.1976).Tofurtherensurethatnaloxonewillantagonizeopioidreceptorsforthestudyentirety,wewilladministerasupplementarymaintenanceintravenousinfusiondoseof0.15mg/kg/hnaloxoneorsalineimmediatelyafterbolusinfusionceases.ThedurationofthestudyfromtheonsetofIVinfusiontocompletionwillbenomorethan25(averagetimeofinfusion=approx.15minutes).Onlythestudyphysicians,researchpharmacist,andstudycoordinatorwillbeawareofparticipantdrugassignment.SampleSizeDetermination&Power:Assumingaconservative20%dropoutrate,wewillrecruitandrandomizeatotalof74cLBPpatients(n=37/group)toamindfulnessmeditationornon-mindfulnessmeditationregimen.Toconductgroupcomparisonsamongthetwoprimaryoutcomes(naloxone+salineinducedchangesinpainintensity+unpleasantness)andtoensureanoveralltypeIerrorrate<0.05,weusedconservativeBonferronicorrections(p=.025)inallpowercalculations.Employingthepilotdatacorrespondingtopreliminaryfindingsandourpreviouswork[22],wefitrepeatedmeasuresANOVAmodelsthatincludeindicatorvariablesforgroup(mindfulnessvs.non-mindfulness),drug(naloxonevs.saline),andsessionorder.Theestimatedsquarerootofmeansquareerrorsis0.23and0.30forpainintensityandpainunpleasantness,respectively.Thirtyparticipantspergroupwillprovide80%powertodetectagroupdifferenceof0.19forpainintensityand0.24forpainunpleasantness.Sucheffectsizesareconsistentwiththoseobservedfromourpilotdata.Statisticalpowerwillbealsogreaterwhenpre-regimenpainratingsareenteredascovariatestoreduceresidualvariance.DataAnalysesandInterpretation:PrimaryOutcome:Ageandsexwillbeenteredascovariatesinallappropriateanalysesifbetweengroupdifferencesexist.Toteststudyhypotheses,a2(group)X2(restvs.manipulation)X3(naloxonevs.saline)repeatedmeasures(RM)ANOVAwillbeemployed.Post-hocpairedsamplest-tests(ineachgroup)willbeconductedtotestthehypothesesthatnon-mindfulnessmeditationbutnotmindfulnessinducedanalgesiawillbereversedbyadministrationofnaloxonebutnotsaline.Exploratoryanalysesmaybeconducted(insupplementarypapers)onthepsychologicalassessments(QuestionnairesforStudyAssessments)tobetterappreciatetherelationshipindispositionalpainandthepotentialchangesinpainresponsesduetotherespectiveinterventions.
Biomedical IRBApplication InstructionsPage 12InclusionofWomenandMinorities:Participantswillincludeallsexesandraces.Weplantoscreenfromover2500cLBPpatientsfromtheACTRI’spainrecruitmentservice,11separateproviders,andthelocalcommunity.BasedonthelatestSanDiego-baseddemographicconsensus,weplantorecruit60%White,16%Asian,7%Black,0.5%NativeAmerican,0.5%PacificIslander,12%Otherrace,5%twoormoreraces(Weexpectthat29%ofourparticipantswillbeHispanicorLatino).Ifnecessarytoobtainminorityrepresentation,under-representedracialgroupswillbetargetedspecificallyforrecruitment.GeneralConsiderations:Dataforallindividualparticipantsrandomizedorexposedtostudydrugwillbepresentedindatalistings.Continuousdatawillbesummarizedusingthefollowingdescriptivesummarystatistics:thenumberofsubjects(n),mean,SD,SE,median,minimumvalue(min),andmaximumvalue(max).Categoricaldatawillbesummarizedusingcountsandpercentages.10.HUMANSUBJECTSTotalnumberofsubjectstobeenrolledatUCSDOurtargetedsamplesizeis60cLBP(30/group).Wehaveexhibitedarelativelylowattritionrateonpreviouswork,thuswerequestpermissiontoenroll74participantswiththegoalofretaining60participants.Age:Agewillrangebetween18and65years.Sex:Wewillhaveequalmalesandfemalesineachgroup.Groupswillbematchedbyageandsex(15males/15females).Ethnicbackground:Wewillincludeallethnicities.Healthstatus:Participantsmusthaveachroniclowbackpaindiagnosis.AllstudyparticipantswillberecruitedfromtheACTRIandthelocalcommunity.WewillemployourNIH-approvedexclusionandinclusioncriteriadelineatedinpreviousstudiesexaminingcLBP[27;37;42]asdescribedbelow.EligibilityCriteria:Patientswillqualifyforthestudyifmedicalevaluationdemonstrateschroniclowbackpainthatisevokedbyliftingthelegs.Existingmedicalrecords,perphysiciandiscretionandlowbackexaminationswillconfirmdiagnosis.Studyphysicianswillconfirmdiagnosis(Fardon2001,Wasan,Davaretal.2005,Jamison,Rossetal.2010,Wasan,Loggiaetal.2011,Fardon,Williamsetal.2014).Inclusioncriteriaincludethosewho:a)arebetween18-65yearsold;b)haveongoingchronicpain(painintensity≥3ona0-10VAS);c)haveradicularpainforatleast3months;d)arenotusingotherpainmanagementprocedures(i.e.CBDoilproducts)duringthestudyperiod;e)arenottakingopioids;f)iffemaleandofachildbearingpotentialage,arenotpregnantornursingmothers;g)havenothadbacksurgerywithinayearofthestudystartdate;h)lacksensory/motordeficitsthatprecludeparticipationinpain-inducingprocedures;i)havenomeditationexperience;j)arestraightlegraisetestpositivek)donothaveanyknownallergiestonaloxoneorsimilardrugs
Biomedical IRBApplication InstructionsPage 13l)donothaveahistoryofsyncopeand/orfearofneedles/blood.11.RECRUITMENTANDPROCEDURESPREPARATORYTORESEARCHPatientswillberecruitedthroughtwoprimarystreams:(1)fromIRBapprovedflyersandrecommendations by UCSD study physiciansand 2) the ResearchMatch website.Wew i l lb e g i ns t u d yrecruitmentafterwehavecompletedallNIHoversightrequirements.Tobeclear:wewillpostIRBapprovedflyersthroughoutthecommunityandUCSDPainMedicinephysicianoffices.Ifaphysicianbelievesapatientisqualifiedforthisstudy,theywillreferthepotentialparticipanttotheflyeratwhichpointtheycanvoluntarilycallthecoordinatortoassesseligibility.WewillnotaccessmedicalrecordsuntilafterwehavepermissionandthesubjectcompletesVisit1’sprocedures.RecruitmentStream1:ThestudywillbeadvertisedonResearchMatchtogaininterestforparticipationinthepilottothiscLBPstudy.Thissitewillallowformembersofthecommunitytoinquireastotheirpotentialinterestsinthestudy’sgoalsandrequirements.RecruitmentStream2:Inaddition,wewillbothadvertisewithflyerswithintheseclinicsthatseethousandsofpatientseachyear.Hence,thesheeraggregateofpotentialcommunityandclinicalsourcesforthisstudywouldsuggestmorethanadequatepotentialforourrecruitmentaims.Thepatient’streatingphysicianwillberequestedtoapproachtheparticipantandintroducethestudy.Thetreatingphysicianwillfurtherdiscusstheresearchstudywiththepotentialparticipantandreferthemtothecoordinator’scontactinformationatwhichpointthepatienthasthediscretiontocontactthestudycoordinator.Therewillbenodirectcontactofthepotentialresearchparticipantbythestudystaffunlesspromptedbythepotentialparticipant.Theirtreatingphysicianscanreferthemtoourstudyandtheywillcallus,iftheychoose,ontheirvolition.Ifapotentialparticipantisinterestedinthestudy.Theywillemailand/orcallthestudycoordinatortoassesseligibility.Thisisstrictlybasedonthepatients’discretionandvolition.Abriefsubsetofpreliminaryeligibilitycriteria(suchasage,gender,etc.),willbereviewedbystudypersonneltodeterminesubjects’preliminaryeligibilityfortheresearchstudyduringthephonescreeningandVisit1.Thephonescreenscriptwillbeemployedtoidentifypreliminarystudyeligibility.Thestudyteammemberscreeningpotentialparticipants,willobtainverbalconsentbeforeanyparticipantinformationiscollected,seeitem12belowforrequestforwaiverofdocumentedconsentforthisscreening.Subjectswhofulfillthepreliminaryeligibilitycriteriawillbeofferedfurtherparticipationinthisstudy.Preliminaryeligibilitymaybedeterminedatthetimeofphonescreening,butformaleligibilitywillonlybedeterminedafterinformedconsentisobtainedandastandard,stand-aloneHIPAAauthorizationformissigned.TheprimarymethodofdeterminingeligibilityforthestudyisthestraightlegraisetestconfirmationduringVisit1.StandardHIPAAauthorizationtocollectresearchdatafromthepatient’smedicalrecordwillbeobtainedatthetimeofinformedconsentduringSession1.OnlysubjectswhohaveconsentedandprovidedHIPAAauthorizationwillhaveidentifiersorlinkedinformation(e.g.,subjectsinitials,studynumbers,etc.)recordedontheScreening/EnrollmentLog.Thestudyfunder(NIH)willnothaveaccesstothesubject’sPHI.Onlyteammembers,asdescribedinitem21,willhaveaccesstothisinformation.Strategies:Diversityandreflectionofregionalpopulation.Geographically,theclinicsattheACTRIserviceabroadportionofthegreaterSanDiegoregion.Moreover,weacceptreferralsfromalloverSouthernCalifornia.Asaresult,ourstudyteamwillrecruitpatientsfromahighlydiversepatientpopulationintermsofrace,sex,andsocioeconomicstatus.Subjectpopulationsinpreviousand
Biomedical IRBApplication InstructionsPage 14ongoingstudieshavereflectedthediversityoftheregionanddisease-specificdemographics.Ifweareunabletoobtainsufficientminorityrepresentationinoursample,under-representedracialgroupswillbespecificallytargetedforrecruitment.Contingencyplans:Shouldtheabovestreamsofrecruitmentproveinadequateforustomeetouraccrualtimetableandkeepourcohortscheduleontrack,wewillreachouttosocialmediaandotherlocalprintandmulti-media-basedadvertisementstrategiesprominentwithintheSanDiegoarea.Thisapproachhasprovedusefulinpaststudiesandshoulddosoagain.Participantswillalsobereimbursed($400)forsuccessfulstudycompletion.Thisapproachhasbeenusefulinmotivatingparticipantstocompletetheirstudyresponsibilitiesinthepast.Ifwefindthattheamountofferedisinadequateformaintainingactiveparticipantengagement,wewillconsiderincreasingit.Thislabhashadagoodtrackrecordwithsubjectaccrualandretentionrates.TheserecruitmentplanshavebeenverysuccessfulatattainingtargetedsamplesizesinpreviousstudiesandhavebeenrecognizedbyUCSDandtheNIHasappropriatemodelsforrecruitmentsuccess.TheResearchPlanwillbeamendedtoincludetheserecruitmentstrategies(andmaterialsifappropriate)astheyareaddedbutpriortotheiruse.12.INFORMEDCONSENTWaiverofDocumentedConsentforAidinginDeterminingPreliminaryEligibilityduringResearchRecruitment:Weareaskingforawaiverofdocumentedconsentwhilerecruitingpatientstoappropriatelyidentifypotentialparticipantswithchroniclowbackpainduringthephonescreeningprocedure.Thephonescreenisconsiderednomorethanlowrisktothepotentialparticipants,sincewewillnotperformanyprocedure,andtheprobabilityandmagnitudeofharmordiscomfortanticipatedinthisresearcharenotgreaterthanthoseordinarilyencounteredindailylife.Inaddition,ourmethodsofrecruitmentdonotallowthepre-screenertodirectlycontactorcallthepatientunlessthepatient,themselves,contactsthestudyteamfirstthroughcontactinformationprovidedonstudyadvertisements orthepatient’streatingphysicianrefersthemtothestudy.Theinformationinquiredaboutandcollectedfromthephonescreenisnecessarytoascertainthepotentialparticipant’ssuitabilityforentryintothestudy.Whilereviewingresponsesandinformationduringthephonescreen,thescreenermaydeterminethatthepotentialparticipantqualifiesforthestudyandthenproceedtoaskiftheywouldbeinterestedinparticipating.Thescreenerwillindicatetopotentialparticipantsthatreviewoftheirmedicalrecordswillbeinvolvedindeterminingformalstudyeligibility.ConsentingProcedures:Patientswillbeaskedtoprovidewrittenconsent,usinganIRB-approvedconsentformduringtheirfirststudysessionattheACTRI.Theconsentprocesswilltakeplacepriortoperforminganystudyrelatedproceduresandinaprivateroomwiththedoorclosed.Thestudyteammemberwilldescribethestudy,includingdetailedinformationaboutrisksandbenefits,topotentialparticipants.ThestudyteammemberwillprovidepotentialparticipantswithanIRB-approvedconsentform.Potentialparticipantswillbegivenampletimetoreadthisconsentformatthesamevisitormaytakeitwiththemtoreadatanothertime.Potentialstudyparticipantswillbegiventheopportunitytoaskandreceiveanswerstoallquestionstheymayhaveaboutthestudy,itsrisksandbenefits,ortheconsentformitselfbeforesigningtheconsentform.AsthisresearchissubjecttoHIPAAprivacyruleprovisions,patientswillalsoberequestedtosignaseparateHIPAAauthorizationfortheuseofprotectedhealthinformation.Thestudyteammemberwillobtaininformedconsentinalanguageunderstoodbytheprospectivesubjectortheirlegallyauthorizedrepresentative,usingcertifiedtranslationsofstudydocumentsthatwillbeuploadedforIRBreviewandapprovaluponthePI’sreceiptofIRBapprovalfortheEnglishversionofthedocument.Certifiedtranslationsofstudydocumentsandqualifiedtranslatorswillbeprovided,whereapplicable.
Biomedical IRBApplication InstructionsPage 15Potentialparticipantswhofulfilltheeligibilitycriteriawillbeofferedfurtherparticipationinthisstudy.OnlyparticipantswhohaveconsentedandprovidedHIPAAauthorizationwillhaveidentifiersorlinkedinformation(e.g.,subjectsinitials,studynumbers,etc.)recordedontheScreening/EnrollmentLog.Allsignedconsentswillbemaintainedinmarkedbinders,securedinlockedfilingcabinetswithinprivateadministrativeofficesatDr.Zeidan’sLaboratoryattheACTRI.Documentationofthisprocesswillbeinwrittenformandplacedintheresearchrecord.Acopyoftheinformedconsentdocumentwillbeplacedinthepatient’smedicalrecord,andacopyhasbeenuploadedforIRBreviewandapproval.Thestudyconsentformwillinclude:1.Whoisconductingthestudy2.Purposeofthestudy3.Whyhe/sheisbeingaskedtoparticipate4.Whatwillhappenduringthestudy5.Thedurationofthestudy6.Potentialrisks7.Potentialofunforeseeablerisks8.Alternativestostudyparticipation9.Benefitsreasonablyexpected10.Careifinjured11.Coststoparticipate12.Paymentforparticipation13.Voluntarynatureofparticipation14.Extentconfidentialityifmaintained15.clinicaltrials.govregistry16.Providedtimetoaskandanswerquestions17.HIPAAdiscussion13.ALTERNATIVESTOSTUDYPARTICIPATIONAsthisisnotatreatmentstudy,theonlyalternativetostudyparticipationistonotparticipate.14.POTENTIALRISKSThisstudymayinvolvesomerisk,althoughtherisksareconsideredlowrisk.StraightLegRaiseTestThestraightlegraisetestmayproducethefeelingofpain.Thegoalistoproduceatargeted30%increase(2-pointincrease)inthefeelingofpainfornomorethan20minutes.Althoughrare(lessthan2%occurrence),participantsmayfeeldiscomfortand/orpainforupto24hours.Thestudyteamwillensureparticipants’comfortand/orsafetyduringthisprocedure.Importantly,participantswillhavecompletecontrolofhowmuchtheyraisetheirleg.ReproductiveRisksDuetounknownrisksandpotentialharmtotheunbornfetus,sexuallyactivewomenofchildbearingpotentialmustuseareliablemethodofbirthcontrolwhileparticipatinginthisstudy.Pregnantwomenareexcludedfromparticipationinthisstudy.Becausesomemethodsofbirthcontrolarenot100%reliable,aurinepregnancytestwillberequiredatleast10daysfromsubjects’lastnormalmenstrualperiod,iftheyareasexuallyactivewomanofchildbearingpotentialandnotusingreliablebirthcontrol.Randomization
Biomedical IRBApplication InstructionsPage 16Participantswillbeinstructedintheconsentformwiththefollowing“Youwillbeassignedtoastudygroupatrandom(bychance).Yourassignmentisbasedonchanceratherthanamedicaldecisionmadebytheresearchers.Thestudygroupyouareassignedtomightnotbethegroupyouwouldprefertobein.Yourassignedstudygroupmightalsoprovetobelesseffectiveorhavemoresideeffectsthantheotherstudygroups(s),orothertreatmentsavailableforyourcondition.Youwillalsoberandomlyadministeredeithernaloxoneorsaline(orviceversa)inexperimentalsessions6and7whichmayinfluencesomeoftheirresponses.”PsychologicalAssessmentsParticipantsmayexperienceeyestrainingwhilecompletingpsychologicalassessments.Inthisrarecase,wewilladjust/increasethefontsizeofourassessmentsonourelectronicdevices.Althoughthishasnotoccurredinourresearchstudies,completingpsychologicalassessmentsmayincreaseemotionaldistress.Ifthisisthecase,wewillaskourparticipantsto“takeabreak”orexcusethemselvesfromthestudy.Wewillalsoreferthemtocounselingservicesifneedbe.Theremaybeaperceptionofpossibleinvasionofprivacyorprobingofinformationthatmightbeconsideredsensitive.Toaddressthisconcern,allmembersoftheresearchteamwillbesensitivetotheneedsofparticipantsbyremindingthemthattheydonotneedtoansweranyquestionsthattheywouldprefernottoanswer,completeanytasksthattheywouldprefernottocomplete,orfollowthroughwithanyprocedurethattheywouldratherdecline.Studystaffwillusetheirclinicaljudgmenttodiscontinueassessmentifaparticipantappearsupset.RespiratoryTransducerandPulseOximeterDuringthecLBPinducingprocedure,thestraightlegraisetest,participantswillbefittedwitharespiratorytransduceraroundthechest.Wehavenotexperiencedanyproblemswiththisdevicehowever,participantsmayfeeluncomfortablewiththeplacingofthisdevice.Wewillinstructparticipantstoinformusifthatisthecase,andwewillmakeadjustments(tighteningorlooseningthedevice’splacement).MeditationRisksAlthoughextremelyrare,longboutsofmeditationpractice(greaterthan3-4hoursatatime),canpotentiallyleadtofeelingsofconfusion,light-headedness,anxiety,sleepiness,andagitation.Further,sittingforlongperiodsoftimecouldcausesorenessinthebody.Participantswillbeinformedatthebeginningofeachsessionthatsimplyopeningtheireyesandmovingcouldaddressalloftheserarerisks.NaloxoneTheuseofhighnaloxoneiscriticallyneededtocomprehensivelyantagonizeendogenousopioids.Thisprocedureiswell-validated,largelysafeinopioidfreeindividualsandhasreliablytestinginanumberofstudies.However,naloxonemayalsoworsenorexacerbatefeelingsofnausea,vomiting,sweating,increasedheartrate,tremors,rapidbreathing,andchangesinbodytemperature,agitation,andexcitement.Althoughextremelyrare,cardiacarrestmayalsooccurasafunctionnaloxoneinfusion.Mostofthesesideeffectsaremildandshort-livediftheyoccuratall.Withdrawalsymptomscanariseifpatientsaretakingopioids.Additionalcarewillalsobeprovidedifanyofthesesymptomsexist.Inourmostrecentpsychophysicalandpharmacologicstudy,60participantswereadministeredintravenousnaloxoneandtherewere0safetyeventsorsideeffectsreported.Inrarecases,naloxonemaycausesideeffectssuchas:nauseaorvomiting,sweating,increasedheartrate,tremor,rapidbreathing,changesinbodytemperature,light-headedness,cloudingofvision,fainting,agitationand/orirritability,restlessnessand/orexcitement.Thoughtheyarehighlyunlikelytooccur,mostofthesesideeffectsaremildandshort-lived,iftheyoccuratall.Naloxonehasrarelybeenassociatedwithpotentiallyfatalcardiacarrhythmiasandevenflagrantcardiacarrest.Additionalcarewillalsobeprovidedifanyofthesesymptomsexist.Further,individualswithahistoryofsyncopeandlightheadedness,fearofneedlesandbloodareexcludedfromthisstudy.TheACTRInursing
Biomedical IRBApplication InstructionsPage 17staffand/oraphysicianwilloverseeallexperimentalprocedureswherenaloxoneisinvolvedtoensurecompleteparticipantsafetyandcomfort.ThermalStimuliThermalstimulimayelicitthefeelingofpainandsometemporaryreddeningoftheskin.Thereistheexceptionallyrarepotentialtoburningoftheskin,althoughthishasnotoccurred.Toaddressthis,weneverstraptheprobetothelimb(recommendeduse)andhavecustomizedaprobeholderthatwillallowtheparticipanttoescapeatanytime.15.RISKMANAGEMENTPROCEDURESANDADEQUACYOFRESOURCESThestudywascarefullydesignedtominimizeornegateanypotentialrisk/discomforttoparticipants.AnIndependentMonitoringCommittee(IMC)willmonitortheactivitiesofthisstudyforpurposesofevaluatingsubjectsafetyandstudyintegrity.ThekeyelementsoftheIMCplanincludeprotectionofparticipantprivacy,databaseprotection,adverseeventreporting,dataqualityandsafetyreports,participantcompliance,andsafetyreviewplans.Fortheproposedstudy,theIMCwillreviewtheprogressofandsafetyafter20,40,60and74(ifneeded)studyparticipantshavecompletedallstudyprocedures.Therewillbenofeefortheindependentmonitoringoftheproposedstudies.Dr.Zeidanwilloverseeallexperimentalproceduresoftheproposedresearchactivities.Intheeventofanadversesafetyevent,protocoldeviationsandadverseeventswillbepromptly(lessthan24hours)reportedtotheIMCandtheIRB.Thisstudywillbestoppedpriortoitscompletionif:(1)theinterventionisassociatedwithadverseeffectsthatcallintoquestionthesafetyoftheintervention;(2)difficultyinstudyrecruitmentorretentionwillsignificantlyimpacttheabilitytoevaluatethestudyendpoints;(3)anynewinformationbecomesavailableduringthetrialthatnecessitatesstoppingthetrial;or(4)othersituationsoccurthatmightwarrantstoppingthetrial.Wedonotanticipateanyeventsthatwouldcauseacessationofthestudy.Wehaverepeatedlydemonstratedtheabilitytoreliablyrecruit,retain,andexecutedatacollectioninafashionthatensuressuccessfulcompletionofourexperiments.However,intheunforeseeablecasethattheproposedstudyhastobestopped,thePIwillincludeanassessmentoffutilityintheannualprogressreporttoNIH.WewillconsultwiththeIMCandNCCIHtoassesstheimpactofsignificantdatalossduetoproblemsassociatedwithstoppingthestudy.StraightLeg-RaiseTest:Thestraightleg-raisetestisacommonlyemployedmaneuvertoexaminechroniclow-backpainseverityandpatientmobility.Intherarecasethatpainexacerbationisincreasedbygreaterthan4VASpointsanddoesnotreturntobaselinelevelsafter40minutes,wewilldiscontinuepatientstudyparticipationwithreimbursementanda physicianwillevaluatetheparticipant.Pregnancy:Duetounknownrisksandpotentialharmtotheunbornfetus,sexuallyactivewomenofchildbearingpotentialmustuseareliablemethodofbirthcontrolwhileparticipatinginthisstudy.Pregnantwomenandnursingmothersareexcludedfromparticipationinthisstudy.Becausesomemethodsofbirthcontrolarenot100%reliable,apregnancytestmayberequiredatleast10daysfromaparticipant’slastnormalmenstrualperiod,iftheyareasexuallyactivewomanofchildbearingpotential.PsychologicalAssessments:Althoughtherearegenerallyverylowriskstocompletingpsychologicalscales,wewillinstruct(verbally;consentform)participantsthatpsychologicalassessmentsmayproduceemotionaldistress.Aclinicalpsychologistmayalsobeavailabletotriageanyconcerns.
Biomedical IRBApplication InstructionsPage 18Respiratorytransducer:Inordertoreduceanydiscomfortfromtherespiratorytransducer,wewillinstructparticipantsto“letusknow”whenthebeltismostcomfortableand/ornotcomfortable.Naloxone:Naloxonewillbeadministeredintravenously.Nauseaorvomiting,sweating,increasedheartrate,tremor,rapidbreathing,changesinbodytemperature;agitationand/orirritability,restlessnessand/orexcitementareknownsideeffectsoftakingnaloxone.Mostofthesesideeffectsaremildandshort-livediftheyoccuratall.Withdrawalsymptomscanariseifpatientsaretakingopioids.Thus,beforeanynaloxone/salineinfusiontestingsession,wewilladministeranopiatefocusedurinescreening.ThermalStimuli:Participantswillexperiencepainfulstimuliproducedbyheatingtheskintotemperaturesfrom35°Cto49°C.StimuliinthistemperaturerangehavebeenusedextensivelybythePIandnumerouslaboratoriesaroundtheworldanddonotproducetissuedamageorburns.Inordertofacilitateescapefromthestimulator,thestimulatorwillbeattachedtoacustom-designedthermalstimulationprobeholder.Participantswillplacetheircalfontopoftheprobeholderandwillnotbestrappedinorotherwiserestrained.Therefore,participantswillbeabletosimplylifttheirlegsatanytime.Furthermore,stimulustemperaturewillbemonitoredcontinuouslywithanexternaldigitalchartrecorderthatisindependentofthemicroprocessorinthestimulator.Specifically,theunprocessedoutputofthetemperaturesensorintheheadofthestimulusprobewillbebothmonitoredandrecorded.Intheeventofasignificantdeviationfromthetargettemperature,theTSA-IIisdesignedtoshutoffautomatically.Ifthedevicedoesnotshutitselfoff,theoperatorwillterminatestimulation.Furthermore,allvolunteerswillbeconscious,lifttheirlegs(respectively)fromtheprobe,andwillbefreetoterminatethestimulus.Intheremoteeventthataburndoesoccur,theaffectedareawillbegentlyrinsedwithcoldwaterandcoveredwithaprotectivebandage.Theparticipantwillthenbereferredtotheburnclinicfortreatment.Allstudyparticipantswillprovideinformedconsent.Theywillberemindedthattheirbehavioraldataisconfidentialandthattheycanrefusetoparticipateand/orwithdrawfromstudyparticipationwithoutexplanationandfinancialreimbursementandthiswouldnotaffecttheirrespectiverelationshipwiththeirphysicians.Theproposedstudywillbeconductedinawaythatassuresprotectionoftherightsandwelfareofsubjects.TheACTRIhasanestablishedhistoryofsuccessfullyandsafelycompletingclinicalstudies.TheproposedNIHsponsored1-yearprojecthasplentyoftimetoensurecompletion.TheACTRIisaworld-renownfacilityknownforemployingthehigheststandardsofclinicalresearchexcellence.WewillconductSessions1,6,and7atthisfacility.AllinterventionsessionswillbeconductedattheUCSDCenterforMindfulness,anestablishedleaderinconductingbehavioralinterventions.Allresearchstaffwillbetrainedtoreliablyconductallactivities.Thisprojectwillincludethestudyteammembersnotedinitem21below.Duetothelowriskofthestudy,wedonotanticipateemergencymedicalcareservices.Asinthenaloxonestudiespreviouslyconductedbythisresearchlab,wearesolelyusinganopiate-focusedurinedrugscreeningasaprecautionarymeasuretoavoidanyconflict,withdrawal,orsideeffectsthatnaloxonewouldelicitifasubjectwaspresentlyusingopiates/opioids.Itisaneligibilityrequirementthatparticipantsarenottakingopioids.Wewillinquireaboutthisthoroughlywitheachparticipantthroughself-reportandmedicalhistoryconfirmation,toensuremaximumsafety.AdverseEvent:AnAEisanyproblematicmedicaloccurrenceinasubjectduringparticipationinthestudy.TheOfficeforHumanResearchProtections(OHRP)considersunanticipatedproblemsinvolvingrisksto
Biomedical IRBApplication InstructionsPage 19subjectsorotherstoinclude,ingeneral,anyincident,experience,oroutcomethatmeetsallofthefollowingcriteria:•Unexpectedintermsofnature,severity,orfrequencygiven(a)theresearchproceduresthataredescribedintheprotocol-relateddocuments,suchastheIRB-approvedresearchprotocolandinformedconsentdocument;and(b)thecharacteristicsofthesubjectpopulationbeingstudied.•Relatedorpossiblyrelatedtoparticipationintheresearch(“possiblyrelated”meansthereisareasonablepossibilitythattheincident,experience,oroutcomemayhavebeencausedbytheproceduresinvolvedintheresearch);and•Suggeststhattheresearchplacessubjectsorothersatagreaterriskofharm(includingphysical,psychological,economic,orsocialharm)thanwaspreviouslyknownorrecognized.•Anyunanticipatedproblems,serious/unexpectedadverseevents,deviationsorprotocolchangeswillbepromptlyreportedtotheIRBandIMC.SeriousAdverseEvent(SAE)Aseriousadverseevent(SAE)isonethatmeetsoneormoreofthefollowingcriteria:•Resultsindeath•Islife-threatening(placesthesubjectatimmediateriskofdeathfromtheeventasitoccurred)•Resultsininpatienthospitalizationorprolongationofexistinghospitalization•Resultsinapersistentorsignificantdisabilityorincapacity•ResultsinacongenitalanomalyorbirthdefectAnimportantmedicaleventthatmaynotresultindeath,belifethreatening,orrequirehospitalizationmaybeconsideredanSAEwhen,baseduponappropriatemedicaljudgment,theeventmayjeopardizethesubjectandmayrequiremedicalorsurgicalinterventiontopreventoneoftheoutcomeslistedinthisdefinition.TimePeriodandFrequencyforEventAssessmentandFollow-Up:Unanticipatedproblemswillberecordedinthedatacollectionsystemthroughoutthestudy.ThePIwillrecordallreportableeventswithstartdatesoccurringanytimeafterinformedconsentisobtaineduntil7(fornon-seriousAEs)or30days(forSAEs)afterthelastdayofstudyparticipation.Ateachstudyvisit,thePIwillinquireabouttheoccurrenceofAE/SAEssincethelastvisit.Eventswillbefollowedforoutcomeinformationuntilresolutionorstabilization.Toassessrelationshipofaneventtostudyintervention,thefollowingguidelinesareused:1.Related(Possible,Probable,Definite)1.Theeventisknowntooccurwiththestudyintervention.2.Thereisatemporalrelationshipbetweentheinterventionandeventonset.3.Theeventabateswhentheinterventionisdiscontinued.4.Theeventreappearsuponare-challengewiththeintervention.2.NotRelated(Unlikely,NotRelated)Thereisnotemporalrelationshipbetweentheinterventionandeventonset.Analternateetiologyhasbeenestablished.ExpectednessofSAEs:ThestudyPIandtheIMCwillberesponsiblefordeterminingwhetheranSAEisexpectedorunexpected.Anadverseeventwillbeconsideredunexpectedifthenature,severity,orfrequencyoftheeventisnotconsistentwiththeriskinformationpreviouslydescribedfortheintervention.SeverityofEvent:Thefollowingscalewillbeusedtogradeadverseevents:Mild:nointerventionrequired;noimpactonactivitiesofdailyliving(ADL)Moderate:minimal,local,ornon-invasiveinterventionindicated;moderateimpactonADL
Biomedical IRBApplication InstructionsPage 20Severe:significantsymptomsrequiringinvasiveintervention;subjectseeksmedicalattention,needsmajorassistancewithADLReportingProcedures:SAEsthatareunanticipated,serious,andpossiblyrelatedtothestudyinterventionwillbepromptlyreportedbytheprincipalinvestigatortotheIRBandIMC.AnticipatedorunrelatedSAEswillbehandledinalessurgentmannerbutwillbereportedtotheIMC,UCSDIRB,NCCIH,andotheroversightorganizationsinaccordancewiththeirrequirements.IntheannualAEsummary,theIMCReportwillstatethattheyhavereviewedallAEreports.ConfidentialityDuringAdverseEvent(AE)Reporting:Alladverseevent(AE)reportsandannualsummarieswillnotincludesubjectorgroup-identifiablematerial.Eachreportwillonlyincludesubjects’SIDs.Anyunanticipatedproblems,seriousandunexpectedadverseevents,deviation/protocolchangeswillbepromptlyreportedbythePItotheIRBandIMC.AEreportsandannualsummarieswillnotincludepatientorgroup-identifiablematerial.Eachreportwillonlyincludesubjects’SIDs.DataandSafetyMonitoring:ThePIandtheIMCwillberesponsiblefortheoverallmonitoringofthedataandsafetyofstudyparticipants.ThePIwillbeassistedbyothermembersofthestudystaff.ReportingofUnanticipatedProblems,AdverseEventsorDeviations:Anyunanticipatedproblems,seriousandunexpectedadverseevents,deviationsorprotocolchangeswillbepromptlyreportedbythePIordesignatedmemberoftheresearchteamtotheIRBandNIHorappropriategovernmentagencyifappropriate.16.PRIVACYANDCONFIDENTIALITYCONSIDERATIONSINCLUDINGDATAACCESSANDMANAGEMENTStudyrecruitmentandenrollmentwillbemonitoredthroughaScreening/EnrollmentLog,bothcreatedaspasswordprotectedMicrosoftExcelspreadsheets.TheScreening/EnrollmentLogwillincludeaparticipant’s:namesourceofcontact(communityvs.clinic),age,diagnosis(spinalpathologyanddate),gender,ethnicity,currentdrugregimen(i.e.mostlyfocusedonopiateusage),handednessandmeditationexperience.TheScreening/EnrollmentLogwillprovidedatescorrespondingtowheninformedconsentwasobtained,theidentified2-pointVASincreaseangle/height(fromthestraightlegraisetest),heightandweightonthedayofthescreening/session1,confirmedeligibility,aswellasanotesectionformiscellaneousnotations.Thisinformationwillbeobtainedfromaphonescreeningandtheirresponseswillbeloggedintothespreadsheet,whereajudgmentwillbemaderegardingtheirsuitabilityforentryintothestudyaccordingtostudyeligibilitycriteria.TheScreening/EnrollmentLogwillbeanalyzedintheinterimbetweencohortstodeterminewhichinputstream(communityvs.clinical)yieldsthehighestpercentageofinputtothestudy.Thisanalysismayproveusefulforfuturetweaksofourrecruitingstrategies.Wewillalsolookatthestreamsourcingwithrespecttocohortdiversity.Wheneverpossible,wewillseektomaximizeethnicandsocioeconomicdiversityinordertobroadentheimplicationsofthestudy’sresults.TheNoidentifyinginformationwillbeusedonanystudydocumentsafterenrollment.Enrolledparticipantswillbeassignedauniquesubjectidentificationnumber(SID)thatwillbeusedonallCRFsandstudyrelated documents after enrollment.The SID will be linked to participant identifiable information (asdescribedinitem9)inaseparateSubjectIdentificationLog,createdandpasswordprotectedinaMicrosoftexcelspreadsheet.Thiswillbestoredonthecoordinator’spasswordprotectedandencryptedcomputeronthe3rdflooroftheACTRI.Allcompletedcasereportforms(CRF),createdforallstudyrelatedvisitrequirements,willkeptinastudybinderatacentralandsecurelocationinourfacilitytobetterfacilitatethetrackingofeachenrolledparticipantandcohort.AllstudyrelateddocumentswithcorrespondingSIDswillbestoredin
Biomedical IRBApplication InstructionsPage 21afolder,inalargercohortbinderthat’sdividedbyeachindividualparticipant.Eachparticipant’sbinderwillbemonitoredperiodically(monthly)toensuresubject’sprogressthroughthestudyaswellaspositiveornegativeprogressionofsymptomsofinterest.Allstudy-relatedsafetyandadverseeventswillbereportedtotheUCSDInstitutionalReviewBoard(IRB)andIMCperappropriatereporting timeframes.All study-related records/information will be made available to the UCSD IRBandIMCatanytimeoftheirchoosing.AllstudydatawillbeprocessedinaHIPPA-compliantfashiontoensureconfidentialityandtoprotectthePHIcollectedfromimproperuseand/ordisclosure.DigitaldatawillbestoredonbothphysicallyandsoftwareprotectedcomputersandwillonlybeaccessedbystudypersonnelfromwithintheACTRIbuilding(coordinatorcomputer).Anyreferencetoindividualsubjectsinreportsofthisworkwillutilizeastudyidentificationnumber(SID)topreserveconfidentiality.Followingdatacollectionparticipantidentifyinginformationwillbedestroyedwhendatacollectionandcorrespondingstatisticalanalysesfortheprimaryaimsarecompleted,consistentwithdatavalidationandstudydesign,producingananonymousanalyticaldataset.Whenthesearecomplete,thestudycoordinator(s)orPIwillshredanyandallphysicaldocumentscontaininganyidentifiers/PHIonit.Ourprimaryaimistoensureparticipantsafetyandconfidentiality;thus,wewilltakethehighestmeasuresandupholdthemoststringentstandardstoensurepatientconfidentiality.17.POTENTIALBENEFITSThisresearchisnotexpectedtodirectlybenefitindividualparticipants,butislikelytoyieldgeneralizableknowledge.Thebasicunderstandingofhowmindbodyapproachesfunctiontoalleviatepainandimprovewellbeingareunknown.Theprimarypurposeoftheproposedstudyistodetermineifendogenousopioidergicsystemsareengagedbymindfulnessmeditationtoreducechroniclowbackpain.Thisworkwillalsoinformwhetherornotmindbodyapproachescanbeutilizedincombinationwithmoretraditionalpaintherapiesbycombiningtwodistinctpainmodulatoryprocesses/therapies.Theknowledgegainedfromthisstudywillprovidenovelmechanisticinsighttobetterdevelopandtailorcognitivetherapeuticinterventionstotargetmultiplechronicpainconditions.18.RISK/BENEFITRATIOThisstudyhasalowrisk,andthepotentialbenefitsoftheproposedstudyoutweightherisksintermsofoverallreward.Theknowledgetobegainedsignificantlyoutweighthelowrisksassociatedwiththisstudy.InlightoftheongoingopioidepidemicandthenewprescribingguidelinesbytheCenterforDiseaseControltoemploynon-opiatebasedtherapies,theidentificationoftheendogenousandphysiologicalmechanismssupportingsuchtherapiesistimelyandofparamountimportance.Onepromisingbehavioraltherapyismindfulness-basedmeditationtraining.However,westilldonotfullyappreciatehowmindfulnessreduceschronicpain.Theprimarypurposeofthisproposedstudyistodetermineifendogenousopioidergicsystemsareengagedbymindfulnessmeditationtoreducechroniclowbackpain.Inquiryintothisworkmayinformhowmindfulnessmeditationcanactaseffectivelyasleadingprescribedopiates,providinganalternativenon-pharmacologicalpaintreatmentoption.Importantly,ifwereplicateourfindingsinhealthyindividuals(i.e.,mindfulness-basedanalgesiaisnotopioidergicallymediated),thenthetreatmentofchronicpainmaybemoreeffectivewithmindfulnessandmoreconventionaltherapiesduetoalackofcross-tolerancewithopiatebasedmedications.Thus,thebenefitssignificantlyoutweighthelowrisksofthisstudy.19.EXPENSETOPARTICIPANTPatientswillhavetopay$4forparkingforeveryvisittotheACTRI(3visitstotheACTRI=$12),andwillberesponsiblefortheirownmethodoftransportation.20.COMPENSATIONFORPARTICIPATIONParticipantswillnotbecompensatedforparkingbutwillreceive$400.00inpro-ratedpaymentsascompensationforparticipationinthisresearch.ParticipantswillbepaidwithVanillaVisaGiftCardsaftereachattendedstudysession.Theywillbepaid$40foreachexperimentalsessionthatpainevokingproceduresareused(3sessions=$120).Foreachmindfulnesssession,theywillbe
Biomedical IRBApplication InstructionsPage 22compensated$10(4sessions=$40).Foreachsessionwherenaloxone/salineisadministered,theywillbecompensated$80(2sessions=$160).Anduponstudycompletion,theywillalsoreceiveanadditional$80forsuccessfullycompletingallstudysessions.Webelievethatthemodeststipendof$400isappropriatewithoutinvokingcoercion.Toreceivepayment,participantsmustprovidetheirsocialsecuritynumber,nameandaddressincompliancewithIRS(InternalRevenueService)reportingrequirements.WhenpaymentsarereportedtotheIRS,thestudyteamwillnotletthemknowwhatthepaymentisfor,onlythatparticipantshavebeenpaid.Ifparticipantsdonotwishtoprovidethisinformation,theycanstilltakepartinthisstudybutwillnotbepaid.22.BIBLIOGRAPHYAdams,J.E.(1976)."Naloxonereversalofanalgesiaproducedbybrainstimulationinthehuman."Pain2(2):161-166.Adler-Neal,A.L.,N.M.Emerson,S.R.Farris,Y.Jung,R.C.CoghillandF.Zeidan(2019)."Brainmoderatorssupportingtherelationshipbetweendepressivemoodandpain."Pain160(9):2028-2035.Adler-Neal,A.L.,C.E.Waugh,E.L.Garland,H.A.Shaltout,D.I.DizandF.Zeidan(2019)."Theroleofheartratevariabilityinmindfulness-basedpainrelief."JPain.Amanzio,M.andF.Benedetti(1999)."Neuropharmacologicaldissectionofplaceboanalgesia:expectation-activatedopioidsystemsversusconditioning-activatedspecificsubsystems."JNeurosci19(1):484-494.Amanzio,M.,A.Pollo,G.MaggiandF.Benedetti(2001)."Responsevariabilitytoanalgesics:arolefornon-specificactivationofendogenousopioids."Pain90(3):205-215.Anderson,W.S.,R.N.Sheth,B.Bencherif,J.J.FrostandJ.N.Campbell(2002)."Naloxoneincreasespaininducedbytopicalcapsaicininhealthyhumanvolunteers."Pain99(1-2):207-216.Andersson,G.B.(1999)."Epidemiologicalfeaturesofchroniclow-backpain."Lancet354(9178):581-585.Apkarian,A.V.,B.R.Krauss,B.E.FredricksonandN.M.Szeverenyi(2001)."Imagingthepainoflowbackpain:functionalmagneticresonanceimagingincombinationwithmonitoringsubjectivepainperceptionallowsthestudyofclinicalpainstates."NeurosciLett299(1-2):57-60.Bencherif,B.,P.N.Fuchs,R.Sheth,R.F.Dannals,J.N.CampbellandJ.J.Frost(2002)."Painactivationofhumansupraspinalopioidpathwaysasdemonstratedby[11C]-carfentanilandpositronemissiontomography(PET)."Pain99(3):589-598.Benedetti,F.(1996)."Theoppositeeffectsoftheopiateantagonistnaloxoneandthecholecystokininantagonistproglumideonplaceboanalgesia."Pain64(3):535-543.Benedetti,F.,C.ArduinoandM.Amanzio(1999)."Somatotopicactivationofopioidsystemsbytarget-directedexpectationsofanalgesia."JNeurosci19(9):3639-3648.Berna,C.,S.Leknes,A.H.Ahmad,R.N.Mhuircheartaigh,G.M.GoodwinandI.Tracey(2018)."Opioid-IndependentandOpioid-MediatedModesofPainModulation."JNeurosci38(42):9047-9058.Brown,C.A.,J.Matthews,M.Fairclough,A.McMahon,E.Barnett,A.Al-Kaysi,W.El-DeredyandA.K.Jones(2015)."Striatalopioidreceptoravailabilityisrelatedtoacuteandchronicpainperceptioninarthritis:doesopioidadaptationincreaseresiliencetochronicpain?"Pain156(11):2267-2275.Bruehl,S.,J.W.Burns,O.Y.ChungandM.Chont(2011)."Interactingeffectsoftraitangerandacuteangerarousalonpain:theroleofendogenousopioids."PsychosomMed73(7):612-619.Bruehl,S.,J.W.Burns,O.Y.ChungandP.Quartana(2008)."Angermanagementstyleandemotionalreactivitytonoxiousstimuliamongchronicpainpatientsandhealthycontrols:theroleofendogenousopioids."HealthPsychol27(2):204-214.Bruehl,S.,J.W.Burns,S.D.Passik,R.Gupta,A.Buvanendran,M.Chont,E.Schuster,D.OrlowskaandC.R.France(2015)."TheContributionofDifferentialOpioidResponsivenesstoIdentificationofOpioidRiskinChronicPainPatients."JPain16(7):666-675.Bruehl,S.andO.Y.Chung(2006)."Parentalhistoryofchronicpainmaybeassociatedwithimpairmentsinendogenousopioidanalgesicsystems."Pain124(3):287-294.
Biomedical IRBApplication InstructionsPage 23Bruehl,S.,O.Y.Chung,J.W.BurnsandS.Biridepalli(2003)."Theassociationbetweenangerexpressionandchronicpainintensity:evidenceforpartialmediationbyendogenousopioiddysfunction."Pain106(3):317-324.Bruehl,S.,O.Y.Chung,J.W.BurnsandL.Diedrich(2007)."Traitangerexpressivenessandpain-inducedbeta-endorphinrelease:supportfortheopioiddysfunctionhypothesis."Pain130(3):208-215.Bruehl,S.,O.Y.Chung,P.WardandB.Johnson(2004)."Endogenousopioidsandchronicpainintensity:interactionswithlevelofdisability."ClinJPain20(5):283-292.Bruno,P.A.,D.P.MillarandD.A.Goertzen(2014)."Inter-rateragreement,sensitivity,andspecificityofthepronehipextensiontestandactivestraightlegraisetest."ChiroprManTherap22:23.Burns,J.W.,S.Bruehl,O.Y.Chung,E.Magid,M.Chont,J.K.Goodlad,W.Gilliam,J.MatsuuraandK.Somar(2009)."Endogenousopioidsmaybuffereffectsofangerarousalonsensitivitytosubsequentpain."Pain146(3):276-282.Burns,J.W.,S.Bruehl,C.R.France,E.Schuster,D.Orlowska,M.Chont,R.K.GuptaandA.Buvanendran(2017)."EndogenousOpioidFunctionandResponsestoMorphine:TheModeratingEffectsofAngerExpressiveness."JPain18(8):923-932.deAndrade,D.C.,A.Mhalla,F.Adam,M.J.TexeiraandD.Bouhassira(2011)."NeuropharmacologicalbasisofrTMS-inducedanalgesia:theroleofendogenousopioids."Pain152(2):320-326.Deyo,R.A.,S.K.Mirza,J.A.TurnerandB.I.Martin(2009)."Overtreatingchronicbackpain:timetobackoff?"JAmBoardFamMed22(1):62-68.DosSantos,M.F.,I.K.Martikainen,T.D.Nascimento,T.M.Love,M.D.Deboer,E.C.Maslowski,A.A.Monteiro,M.B.Vincent,J.K.ZubietaandA.F.DaSilva(2012)."Reducedbasalgangliamu-opioidreceptoravailabilityintrigeminalneuropathicpain:apilotstudy."MolPain8:74.Dowell,D.,T.M.HaegerichandR.Chou(2016)."CDCGuidelineforPrescribingOpioidsforChronicPain-UnitedStates,2016."MMWRRecommRep65(1):1-49.Eippert,F.,U.Bingel,E.D.Schoell,J.Yacubian,R.Klinger,J.LorenzandC.Buchel(2009)."Activationoftheopioidergicdescendingpaincontrolsystemunderliesplaceboanalgesia."Neuron63(4):533-543.Fardon,D.F.(2001)."Nomenclatureandclassificationoflumbardiscpathology."Spine(PhilaPa1976)26(5):461-462.Fardon,D.F.,A.L.Williams,E.J.Dohring,F.R.Murtagh,S.L.GabrielRothmanandG.K.Sze(2014)."Lumbardiscnomenclature:version2.0:RecommendationsofthecombinedtaskforcesoftheNorthAmericanSpineSociety,theAmericanSocietyofSpineRadiologyandtheAmericanSocietyofNeuroradiology."SpineJ14(11):2525-2545.Goldstein,A.andP.Grevert(1978)."Placeboanalgesia,endorphins,andnaloxone."Lancet2(8104-5):1385.Gracely,R.H.,R.Dubner,P.J.WolskeeandW.R.Deeter(1983)."Placeboandnaloxonecanalterpost-surgicalpainbyseparatemechanisms."Nature306(5940):264-265.Grevert,P.,L.H.AlbertandA.Goldstein(1983)."Partialantagonismofplaceboanalgesiabynaloxone."Pain16(2):129-143.Han,B.,W.M.Compton,C.M.JonesandR.Cai(2015)."NonmedicalPrescriptionOpioidUseandUseDisordersAmongAdultsAged18Through64YearsintheUnitedStates,2003-2013."JAMA314(14):1468-1478.Harris,R.E.,D.J.Clauw,D.J.Scott,S.A.McLean,R.H.GracelyandJ.K.Zubieta(2007)."Decreasedcentralmu-opioidreceptoravailabilityinfibromyalgia."JNeurosci27(37):10000-10006.Hosobuchi,Y.,J.E.AdamsandR.Linchitz(1977)."Painreliefbyelectricalstimulationofthecentralgraymatterinhumansanditsreversalbynaloxone."Science197(4299):183-186.Hoy,D.,C.Bain,G.Williams,L.March,P.Brooks,F.Blyth,A.Woolf,T.VosandR.Buchbinder(2012)."Asystematicreviewoftheglobalprevalenceoflowbackpain."ArthritisRheum64(6):2028-2037.InstituteofMedicine(US)CommitteeonAdvancingPainResearch,C.,andEducation(2011).RelievingPaininAmerica:ABlueprintforTransformingPrevention,Care,Education,andResearch.WashingtonD.C,NationalAcademiesPress.
Biomedical IRBApplication InstructionsPage 24Jacob,J.A.(2016)."AsOpioidPrescribingGuidelinesTighten,MindfulnessMeditationHoldsPromiseforPainRelief."JAMA315(22):2385-2387.Jamison,R.N.,E.L.Ross,E.Michna,L.Q.Chen,C.HolcombandA.D.Wasan(2010)."Substancemisusetreatmentforhigh-riskchronicpainpatientsonopioidtherapy:arandomizedtrial."Pain150(3):390-400.Jones,A.K.,V.J.Cunningham,S.Ha-Kawa,T.Fujiwara,S.K.Luthra,S.Silva,S.DerbyshireandT.Jones(1994)."Changesincentralopioidreceptorbindinginrelationtoinflammationandpaininpatientswithrheumatoidarthritis."BrJRheumatol33(10):909-916.Jones,A.K.,N.D.Kitchen,H.Watabe,V.J.Cunningham,T.Jones,S.K.LuthraandD.G.Thomas(1999)."Measurementofchangesinopioidreceptorbindinginvivoduringtrigeminalneuralgicpainusing[11C]diprenorphineandpositronemissiontomography."JCerebBloodFlowMetab19(7):803-808.Jones,A.K.,H.Watabe,V.J.CunninghamandT.Jones(2004)."Cerebraldecreasesinopioidreceptorbindinginpatientswithcentralneuropathicpainmeasuredby[11C]diprenorphinebindingandPET."EurJPain8(5):479-485.Klega,A.,T.Eberle,H.G.Buchholz,S.Maus,C.Maihofner,M.SchreckenbergerandF.Birklein(2010)."Centralopioidergicneurotransmissionincomplexregionalpainsyndrome."Neurology75(2):129-136.Kwong,E.H.,N.Virani,M.Robert,K.Gerry,A.Harding,M.S.Rose,S.P.DukelowandP.M.Barton(2013)."Inter-raterreliabilityoftheActiveStraight-LegRaiseandOne-LegStandingtestsinnon-pregnantwomen."JRehabilMed45(10):1058-1064.Levine,J.D.andN.C.Gordon(1986)."Methodofadministrationdeterminestheeffectofnaloxoneonpain."BrainRes365(2):377-378.Levine,J.D.,N.C.GordonandH.L.Fields(1978)."Themechanismofplaceboanalgesia."Lancet2(8091):654-657.Lobanov,O.V.,F.Zeidan,J.G.McHaffie,R.A.KraftandR.C.Coghill(2014)."Fromcuetomeaning:brainmechanismssupportingtheconstructionofexpectationsofpain."Pain155(1):129-136.Loggia,M.L.,J.Kim,R.L.Gollub,M.G.Vangel,I.Kirsch,J.Kong,A.D.WasanandV.Napadow(2013)."Defaultmodenetworkconnectivityencodesclinicalpain:anarterialspinlabelingstudy."Pain154(1):24-33.Maarrawi,J.,R.Peyron,P.Mertens,N.Costes,M.Magnin,M.Sindou,B.LaurentandL.Garcia-Larrea(2007)."Differentialbrainopioidreceptoravailabilityincentralandperipheralneuropathicpain."Pain127(1-2):183-194.Mangold,D.,M.E.McCaul,M.AliandG.S.Wand(2000)."Plasmaadrenocorticotropinresponsestoopioidblockadewithnaloxone:generatingadose-responsecurveinasinglesession."BiolPsychiatry48(4):310-314.Martikainen,I.K.,M.Pecina,T.M.Love,E.B.Nuechterlein,C.M.Cummiford,C.R.Green,R.E.Harris,C.S.StohlerandJ.K.Zubieta(2013)."Alterationsinendogenousopioidfunctionalmeasuresinchronicbackpain."JNeurosci33(37):14729-14737.May,L.M.,P.Kosek,F.ZeidanandE.T.Berkman(2018)."EnhancementofMeditationAnalgesiabyOpioidAntagonistinExperiencedMeditators."PsychosomMed.Mayer,D.J.,D.D.PriceandA.Rafii(1977)."Antagonismofacupunctureanalgesiainmanbythenarcoticantagonistnaloxone."BrainRes121(2):368-372.Mens,J.M.,A.Vleeming,C.J.Snĳders,H.J.StamandA.Z.Ginai(1999)."Theactivestraightlegraisingtestandmobilityofthepelvicjoints."EurSpineJ8(6):468-473.Nelson,L.S.,D.N.JuurlinkandJ.Perrone(2015)."AddressingtheOpioidEpidemic."JAMA314(14):1453-1454.Ngai,S.H.,B.A.Berkowitz,J.C.Yang,J.HempsteadandS.Spector(1976)."Pharmacokineticsofnaloxoneinratsandinman:basisforitspotencyandshortdurationofaction."Anesthesiology44(5):398-401.
Biomedical IRBApplication InstructionsPage 25Pereira,M.P.,M.U.Werner,T.K.Ringsted,M.C.Rowbotham,B.K.TaylorandJ.B.Dahl(2013)."Doesnaloxonereinstatesecondaryhyperalgesiainhumansafterresolutionofaburninjury?Aplacebo-controlled,double-blind,randomized,cross-overstudy."PLoSOne8(5):e64608.Posner,J.andC.A.Burke(1985)."Theeffectsofnaloxoneonopiateandplaceboanalgesiainhealthyvolunteers."Psychopharmacology(Berl)87(4):468-472.Rebain,R.,G.D.BaxterandS.McDonough(2002)."Asystematicreviewofthepassivestraightlegraisingtestasadiagnosticaidforlowbackpain(1989to2000)."Spine(PhilaPa1976)27(17):E388-395.Rosier,E.M.,M.J.IadarolaandR.C.Coghill(2002)."Reproducibilityofpainmeasurementandpainperception."Pain98(1-2):205-216.Roussel,N.A.,J.Nĳs,S.Truĳen,L.SmeuninxandG.Stassĳns(2007)."Lowbackpain:clinimetricpropertiesoftheTrendelenburgtest,activestraightlegraisetest,andbreathingpatternduringactivestraightlegraising."JManipulativePhysiolTher30(4):270-278.Saloner,B.andS.Karthikeyan(2015)."ChangesinSubstanceAbuseTreatmentUseAmongIndividualsWithOpioidUseDisordersintheUnitedStates,2004-2013."JAMA314(14):1515-1517.Schoell,E.D.,U.Bingel,F.Eippert,J.Yacubian,K.Christiansen,H.Andresen,A.MayandC.Buechel(2013)."Theeffectofopioidreceptorblockadeontheneuralprocessingofthermalstimuli."PLoSOne5(8):e12344.Sharma,H.A.,R.GuptaandW.Olivero(2011)."fMRIinpatientswithlumbardiscdisease:aparadigmtostudypatientsovertime."JPainRes4:401-405.Skrabanek,P.(1978)."Naloxoneandplacebo."Lancet2(8093):791.Spiegel,D.andL.H.Albert(1983)."Naloxonefailstoreversehypnoticalleviationofchronicpain."Psychopharmacology(Berl)81(2):140-143.Springborg,A.D.,E.K.Jensen,B.K.TaylorandM.U.Werner(2016)."Effectsoftarget-controlledinfusionofhigh-dosenaloxoneonpainandhyperalgesiainahumanthermalinjurymodel:astudyprotocol:Arandomized,double-blind,placebo-controlled,crossovertrialwithanenricheddesign."Medicine(Baltimore)95(46):e5336.Steglitz,J.,Buscemi,J.,Ferguson,M.J.(2012)."Thefutureofpainresearch,education,andtreatment:asummaryoftheIOMreport“RelievingpaininAmerican:ablueprintfortransformingprevention,care,education,andresearch”."TranslBehavMed2(1):6-8.Stephenson,J.B.(1978)."Reversalofhypnosis-inducedanalgesiabynaloxone."Lancet2(8097):991-992.Summers,B.,K.MalhanandV.Cassar-Pullicino(2005)."Lowbackpainonpassivestraightlegraising:theanteriorthecaasasourceofpain."Spine(PhilaPa1976)30(3):342-345.Taylor,J.J.,J.J.Borckardt,M.Canterberry,X.Li,C.A.Hanlon,T.R.BrownandM.S.George(2013)."Naloxone-ReversibleModulationofPainCircuitrybyLeftPrefrontalrTMS."Neuropsychopharmacology.Taylor,J.J.,J.J.BorckardtandM.S.George(2012)."EndogenousopioidsmediateleftdorsolateralprefrontalcortexrTMS-inducedanalgesia."Pain153(6):1219-1225.Thompson,S.J.,M.H.Pitcher,L.S.Stone,F.Tarum,G.Niu,X.Chen,D.O.Kiesewetter,P.SchweinhardtandM.C.Bushnell(2018)."Chronicneuropathicpainreducesopioidreceptoravailabilitywithassociatedanhedoniainrat."Pain.Wasan,A.D.,G.DavarandR.Jamison(2005)."Theassociationbetweennegativeaffectandopioidanalgesiainpatientswithdiscogeniclowbackpain."Pain117(3):450-461.Wasan,A.D.,M.L.Loggia,L.Q.Chen,V.Napadow,J.KongandR.L.Gollub(2011)."Neuralcorrelatesofchroniclowbackpainmeasuredbyarterialspinlabeling."Anesthesiology115(2):364-374.Zeidan,F.,A.L.Adler-Neal,R.E.Wells,E.Stagnaro,L.M.May,J.C.Eisenach,J.G.McHaffieandR.C.Coghill(2016)."Mindfulness-Meditation-BasedPainReliefIsNotMediatedbyEndogenousOpioids."JNeurosci36(11):3391-3397.Zeidan,F.,N.M.Emerson,S.R.Farris,J.N.Ray,Y.Jung,J.G.McHaffieandR.C.Coghill(2015)."MindfulnessMeditation-BasedPainReliefEmploysDifferentNeuralMechanismsThanPlaceboandShamMindfulnessMeditation-InducedAnalgesia."JNeurosci35(46):15307-15325.
Biomedical IRBApplication InstructionsPage 26Zeidan,F.,N.S.Gordon,J.MerchantandP.Goolkasian(2010)."Theeffectsofbriefmindfulnessmeditationtrainingonexperimentallyinducedpain."JPain11(3):199-209.Zeidan,F.,J.A.Grant,C.A.Brown,J.G.McHaffieandR.C.Coghill(2012)."Mindfulnessmeditation-relatedpainrelief:evidenceforuniquebrainmechanismsintheregulationofpain."NeurosciLett520(2):165-173.Zeidan,F.,S.K.Johnson,B.J.Diamond,Z.DavidandP.Goolkasian(2010)."Mindfulnessmeditationimprovescognition:evidenceofbriefmentaltraining."ConsciousCogn19(2):597-605.Zeidan,F.,S.K.Johnson,N.S.GordonandP.Goolkasian(2010)."Effectsofbriefandshammindfulnessmeditationonmoodandcardiovascularvariables."JAlternComplementMed16(8):867-873.Zeidan,F.,O.V.Lobanov,R.A.KraftandR.C.Coghill(2015)."Brainmechanismssupportingviolatedexpectationsofpain."Pain156(9):1772-1785.Zeidan,F.,O.V.Lobanov,R.A.KraftandR.C.Coghill(2015)."BrainMechanismsSupportingViolatedExpectationsofPain."Pain.Zeidan,F.,K.T.Martucci,R.A.Kraft,N.S.Gordon,J.G.McHaffieandR.C.Coghill(2011)."Brainmechanismssupportingthemodulationofpainbymindfulnessmeditation."JNeurosci31(14):5540-5548.Zeidan,F.,K.T.Martucci,R.A.Kraft,J.G.McHaffieandR.C.Coghill(2014)."Neuralcorrelatesofmindfulnessmeditation-relatedanxietyrelief."SocCognAffectNeurosci9(6):751-759.Zeidan,F.,T.Salomons,S.R.Farris,N.M.Emerson,A.Adler-Neal,Y.JungandR.C.Coghill(2018)."Neuralmechanismssupportingtherelationshipbetweendispositionalmindfulnessandpain."Pain159(12):2477-2485.Zubieta,J.K.,Y.R.Smith,J.A.Bueller,Y.Xu,M.R.Kilbourn,D.M.Jewett,C.R.Meyer,R.A.KoeppeandC.S.Stohler(2001)."Regionalmuopioidreceptorregulationofsensoryandaffectivedimensionsofpain."Science293(5528):311-315.Zubieta,J.K.,Y.R.Smith,J.A.Bueller,Y.Xu,M.R.Kilbourn,D.M.Jewett,C.R.Meyer,R.A.KoeppeandC.S.Stohler(2002)."mu-opioidreceptor-mediatedantinociceptiveresponsesdifferinmenandwomen."JNeurosci22(12):5100-5107.23.FUNDINGSUPPORTFORTHISSTUDYTheproposedstudyisanR21fundedbytheNationalCenterforComplementaryandIntegrativeHealth(NCCIH).ThegrantwillgothroughUSCDasanexistinggrant.ThecorrespondingprogramofficeratNCCIHforthisgrantwillbeDr.InnaBelferatinna.belfer@nih.gov,301-435-1573.24.BIOLOGICALMATERIALSTRANSFERAGREEMENTNotapplicable.25.INVESTIGATIONALDRUGFACTSHEETANDIND/IDEHOLDERINDExemptionForm(attached)26.IMPACTONSTAFFNotapplicable27.CONFLICTOFINTERESTThePIandallkeypersonnelreportnoconflictsofinterest.28.SUPPLEMENTALINSTRUCTIONSFORCANCER-RELATEDSTUDIESNotapplicable29.OTHERAPPROVALS/REGULATEDMATERIALSNotapplicable
Biomedical IRBApplication InstructionsPage 2730.PROCEDURESFORSURROGATECONSENTAND/ORDECISIONALCAPACITYASSESSMENTNotapplicable